US20130144064A1 - Microbiocidal heterocycles - Google Patents

Microbiocidal heterocycles Download PDF

Info

Publication number
US20130144064A1
US20130144064A1 US13/759,761 US201313759761A US2013144064A1 US 20130144064 A1 US20130144064 A1 US 20130144064A1 US 201313759761 A US201313759761 A US 201313759761A US 2013144064 A1 US2013144064 A1 US 2013144064A1
Authority
US
United States
Prior art keywords
formula
compounds
compound
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/759,761
Inventor
Sarah Sulzer-Mosse
Clemens Lamberth
Laura Quaranta
Mathias Stephan Respondek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Crop Protection LLC
Original Assignee
Syngenta Crop Protection LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Crop Protection LLC filed Critical Syngenta Crop Protection LLC
Priority to US13/759,761 priority Critical patent/US20130144064A1/en
Publication of US20130144064A1 publication Critical patent/US20130144064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to heterocycles, e.g. as active ingredients, which have microbiocidal activity, in particular fungicidal activity.
  • the invention also relates to preparation of these heterocycles, to heterocyclic derivatives used as intermediates in the preparation of these heterocycles, to preparation of these intermediates, to agrochemical compositions which comprise at least one of the heterocycles, to preparation of these compositions and to use of the heterocycles or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.
  • the present invention provides compounds of formula I:
  • A is x-C(R 10 R 11 )—C( ⁇ O)—, x-C(R 12 R 13 )—C( ⁇ S)—, x-O—C( ⁇ O)—, x-O—C( ⁇ S)—, x-N(R 14 )—C( ⁇ O)—, x-N(R 15 )—C( ⁇ S)—, x-C(R 18 R 17 )—SO 2 — or x-N ⁇ C(R 30 )— in each case x indicates the bond that is connected to R 1 ;
  • T is CR 18 or N
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N;
  • Q is O or S
  • R 1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino;
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 16 , R 17 , R 18 , R 19 and R 30 each independently are hydrogen, halogen, cyano, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl;
  • R 8 , R 14 and R 15 each independently are hydrogen or C 1 -C 4 alkyl; and
  • R 9 is phenyl, pyridyl, imidazolyl, or
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino; or a salt or a N-oxide thereof.
  • substituents are indicated as being optionally substituted, this means that they may or may not carry one or more identical or different substituents. Normally not more than three such optional substituents are present at the same time.
  • halogen stands for fluorine, chlorine, bromine or iodine.
  • amino stands for —NH 2 .
  • Alkyl, alkenyl or alkynyl substituents may be straight-chained or branched.
  • Alkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and the isomers thereof, for example, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-amyl or pivaloyl.
  • a haloalkyl group may contain one or more identical or different halogen atoms and, for example, may stand for CH 2 Cl 1 , CHCl 2 , CCl 3 , CH 2 F, CHF 2 , CF 3 , CF 3 CH 2 , CH 3 CF 2 , CF 3 CF 2 or CCl 3 CCl 2 .
  • the presence of one or more possible asymmetric carbon atoms in a compound of formula I means that the compounds may occur in optically isomeric froms, i.e. enantiomeric or diastereomeric forms.
  • geometric isomerism may occur, i.e. cis-trans or (E)-(Z) isomerism.
  • atropisomers may occur as a result of restricted rotation about a single bond.
  • Formula I is intended to include all those possible isomeric forms and mixtures thereof.
  • the present invention includes all those possible isomeric forms and mixtures thereof for a compound of formula I.
  • formula I is intended to include all possible tautomers.
  • the present invention includes all possible tautomeric forms for a compound of formula I.
  • the compounds of formula I according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.
  • N-oxides are oxidized forms of teriary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.
  • Suitable salts of the compounds of formula I include those resulting after addition of acid such as those with an inorganic mineral acid e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid, or an organic carboxylic acid e.g. oxalic, tartaric, lactic, butyric, toluic, hexanoic or phthalic acid, or a sulfonic acid e.g. methane, benzene or toluene sulfonic acid.
  • an inorganic mineral acid e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid
  • organic carboxylic acid e.g. oxalic, tartaric, lactic, butyric, toluic, hexanoic or phthalic acid
  • a sulfonic acid e.g. methane, benzene or toluene sulfonic acid
  • the compound of formula I is a compound wherein:
  • A is x-C(R 19 R 11 )—C( ⁇ O)—, x-C(R 12 R 13 )—C( ⁇ S)—, x-O—C( ⁇ O)—, x-O—C( ⁇ S)—, x-N(R 14 )—C( ⁇ O)—, x-N(R 15 )—C( ⁇ S)— or x-C(R 16 R 17 )—SO 2 —, in each case x indicates the bond that is connected to R 1 ;
  • T is CR 18 or N
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N;
  • Q is O or S
  • R 1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino;
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 16 , R 17 , R 18 and R 19 each independently are hydrogen, halogen, cyano, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl;
  • R 8 , R 14 and R 15 each independently are hydrogen or C 1 -C 4 alkyl; and
  • R 9 is phenyl, benzyl, benzyl, benzyl, benzyl
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino; or a salt or a N-oxide thereof.
  • the compound of formula I is a compound wherein:
  • A is x-C(R 10 R 11 )—C( ⁇ O)—, x-C(R 12 R 13 )—C( ⁇ S)—, x-O—C( ⁇ O)—, x-O—C( ⁇ S)—, or x-C(R 16 R 17 )—SO 2 —, in each case x indicates the bond that is connected to R 1 ;
  • T is CR 18 or N
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CR 19 ;
  • Q is O or S
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino.
  • the compound of formula I is a compound wherein:
  • A is x-CR 10 R 11 —C( ⁇ O)—, x-O—C( ⁇ O)—, or x-CR 16 R 17 —SO 2 —, in each case x indicates the bond that is connected to R 1 ;
  • T is CR 19 ;
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CR 19 and providing that there are no N—N bonds in the ring containing Y 1 , Y 2 , Y 3 , and Y 4 ;
  • Q is O or S
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy and halogen.
  • the compound of formula I is a compound wherein:
  • A is x-CH 2 —C( ⁇ O)—, x-O—C( ⁇ O)— or x-CH 2 —SO 2 —, in each case x indicates the bond that is connected to R 1 ;
  • T CH
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CH or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CH and providing that there are no N—N bonds in the ring containing Y 1 , Y 2 , Y 3 , and Y 4 ;
  • phenyl and group (b) are each optionally substituted with 1 to 3 substituents independently selected from halogen, C 1 -C 4 alkyl and C 1 -C 4 haloalkyl;
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each hydrogen;
  • R 8 is hydrogen or methyl;
  • R 9 is phenyl, benzyl or group (a)
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy and halogen.
  • the compound of formula I is a compound wherein:
  • A is x-CH 2 —C( ⁇ O)—, wherein x indicates the bond that is connected to R 1 ;
  • T CH
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CH;
  • R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen, halogen, methyl and halomethyl;
  • R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are each hydrogen;
  • R 8 is hydrogen or methyl;
  • R 9 is phenyl, benzyl or group (a)
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from methyl, halomethyl, and halogen.
  • the invention also relates to compounds of formula I wherein
  • A is x-CH 2 —C( ⁇ O)—, x-CH 2 C( ⁇ S)—, x-OC( ⁇ O)—, x-CH 2 SO 2 —, in each case x being the bond to R 1 ;
  • T CH or N
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CH or N, providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CH and providing that there are no N—N bonds in the ring containing Y 1 , Y 2 , Y 3 ;
  • Q is O or S
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each hydrogen; R 8 is hydrogen or methyl; R 9 is group (i), (j), or (k):
  • A is x-C(R 10 R 11 )—C( ⁇ O)—, x-C(R 12 R 13 )—C( ⁇ S)—, x-O—C( ⁇ O)—, x-O—C( ⁇ S)—, x-N(R 14 )—C( ⁇ O)—, x-N(R 15 )—C( ⁇ S)— or x-C(R 16 R 17 )—SO 2 —, in each case x indicates the bond that is connected to R 1 .
  • A is x-C(R 10 R 11 )—C( ⁇ O)—, x-C(R 12 R 13 )—C( ⁇ S)—, x-O—C( ⁇ O)—, x-O—C( ⁇ S)—, or x-C(R 16 R 17 )—SO 2 —, in each case x indicates the bond that is connected to R 1 . More preferably, A is x-CR 10 R 11 —C( ⁇ O)—, x-O—C( ⁇ O)—, or x-CR 16 R 17 —SO 2 —, in each case x indicates the bond that is connected to R 1 .
  • A is x-CH 2 —C( ⁇ O)—, x-CH 2 C( ⁇ S)—, x-OC( ⁇ O)—, x-CH 2 SO 2 —, in each case x indicates the bond that is connected to R 1 .
  • A is x-CH 2 —C( ⁇ O)—, x-O—C( ⁇ O)— or x-CH 2 —SO 2 —, in each case x indicates the bond that is connected to R 1 .
  • A is x-CH 2 —C( ⁇ O)—, wherein x indicates the bond that is connected to R 1 .
  • T is CR 18 or N.
  • T is CH or N.
  • T is CH.
  • n 1 or 2.
  • n is 2.
  • p is 1 or 2, providing that when n is 2, p is 1.
  • p is 1.
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N, e.g. Y 1 , Y 2 , Y 3 , and Y 4 may be independently CH or N. More preferably, Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CR 19 .
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CR 19 or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CR 19 and providing that there are no N—N bonds in the ring containing Y 1 , Y 2 , Y 3 , and Y 4 .
  • Y 1 , Y 2 , Y 3 , and Y 4 are independently CH or N providing that at least 2 of Y 1 , Y 2 , Y 3 , and Y 4 are CH and providing that there are no N—N bonds in the ring containing Y 1 , Y 2 , Y 3 , and Y 4 .
  • Q is O or S.
  • Q is O.
  • R 1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino.
  • R 1 is phenyl or pyrazolyl; wherein the phenyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy, and amino.
  • R 1 is phenyl or pyrazolyl, wherein the phenyl and pyrazolyl are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, and halogen. Yet more preferably, R 1 is phenyl or group (b):
  • R 1 is phenyl or group (b):
  • phenyl and group (b) are each optionally substituted with 1 to 3 substituents independently selected from halogen, methyl and halomethyl.
  • R 1 is selected from group (c) or (d):
  • R 22 , R 23 , R 24 and R 25 are independently selected from hydrogen, halogen, methyl and halomethyl.
  • R 1 is group (e), (f), (g), or (h):
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 16 , R 17 , R 18 and R 19 each independently are hydrogen, halogen, cyano, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl. More preferably, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 12 , R 13 , R 16 , R 17 , R 18 , and R 19 each independently are hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl.
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 16 , R 17 , R 18 , and R 19 each independently are hydrogen, fluoro, or methyl. Yet more preferably, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 16 , R 17 , R 18 , and R 19 each are hydrogen.
  • R 8 , R 14 and R 15 each independently are hydrogen or C 1 -C 4 alkyl.
  • R 8 , R 14 and R 15 each independently are hydrogen or methyl.
  • R 8 , R 14 and R 15 each are hydrogen.
  • R 9 is phenyl, benzyl or group (a):
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, halogen, cyano, hydroxy and amino.
  • R 9 is phenyl, benzyl or group (a):
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxy and halogen. More preferably, R 9 is phenyl, benzyl or group (a):
  • phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from methyl, halomethyl, and halogen.
  • R 9 is (i), (j), or (k):
  • R 22 is hydrogen or CF 3 .
  • R 23 , R 24 , and R 25 are independently hydrogen or methyl.
  • R 30 is hydrogen, halogen, cyano, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl.
  • R 30 is hydrogen, halogen, C 1 -C 4 alkyl, or C 1 -C 4 haloalkyl.
  • R 30 is hydrogen, fluoro, or methyl. More preferably, R 30 is hydrogen.
  • At least two of Y 1 , Y 2 , Y 3 and Y 4 are CH and the others of Y 1 , Y 2 , Y 3 and Y 4 are CH or N.
  • At least three of Y 1 , Y 2 , Y 3 and Y 4 are CH and the other of Y 1 , Y 2 , Y 3 and Y 4 is CH or N.
  • Y 1 and Y 4 are CH, one of Y 2 and Y 3 is CH and the other of Y 2 and Y 3 is CH or N.
  • Y 1 , Y 2 and Y 4 are CH, and Y 3 is N.
  • Y 1 , Y 3 and Y 4 are CH, and Y 2 is N.
  • Y 1 , Y 2 , Y 3 and Y 4 are CH.
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are H.
  • x-CH 2 —C( ⁇ O)— in which x represents the bond that is connected to R 1 .
  • R 8 is hydrogen
  • A, T, Y 1 , Y 2 , Y 3 , Y 4 , Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I.
  • A, T, G, Y 1 , Y 2 , Y 3 , Y 4 , Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I.
  • A, T, G, Y 1 , Y 2 , Y 3 , Y 4 , Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I.
  • the invention also relates to compounds of formula IA, formula IB, and formula IC as shown above.
  • the invention also relates to compounds of formula ID:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I as defined above.
  • Preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
  • the invention also relates to compounds of formula IE:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I as defined above.
  • Preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
  • the invention also relates to a compound of formula IF:
  • T is N or CH; Y 2 and Y 3 are both CH, or one of Y 3 and Y 2 is N and the other is CH; and R 1 and R 9 are as described for a compound of formula I as defined above. Preferred definitions of R 1 and R 9 are as as defined above
  • the invention also relates to a compound of formula IG:
  • T is N or CH; Y 2 and Y 3 are both CH, or one of Y 3 and Y 2 is N and the other is CH; and R 9 is as described for a compound of formula I as defined above. Preferred definitions of R 9 are as defined above.
  • the invention also includes compounds of formula I in which R 1 is a protecting group, such as an alkyl group. Accordingly the invention includes compounds of formula I.a:
  • R 1′ is C 1 -C 8 alkyl, e.g. C 1 -C 4 alkyl, preferably tert-butyl
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, T, n, p, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 have the definitions as described for formula I as defined above.
  • the invention also relates to other intermediates useful in the preparation of compounds of formula I. Accordingly, the invention relates to a compound of formula II:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, T, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the definitions as described for formula I as defined above.
  • Preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, T, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above.
  • the invention relates to a compound of formula IV:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, T, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the definitions as described for formula I as defined above, and preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, T, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above; and R 26 is C 1 -C 6 alkyl or optionally substituted aryl.
  • R 26 is C 1 -C 6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • the invention relates to a compound of formula V:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, n, p, R 1 , R 2 , R 3 , R 4 , R 6 and R 7 have the definitions as described for formula I as defined above, and preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, n, p, R 1 , R 2 , R 3 , R 4 , R 6 and R 7 are as defined above; and R 26 is C 1 -C 6 alkyl or optionally substituted aryl.
  • R 26 is C 1 -C 6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • the invention relates to a compound of formula X:
  • Y 1 , Y 2 , Y 3 , Y 4 , Q, n, p, R 2 , R 3 , R 4 , R 6 and R 7 have the definitions as described for formula I as defined above, and preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , Q, n, p, R 2 , R 3 , R 4 , R 6 and R 7 are as defined above; and R 26 is C 1 -C 6 alkyl or optionally substituted aryl.
  • R 26 is C 1 -C 6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • the invention relates to a compound of formula XI:
  • Y 1 , Y 2 , Y 3 , Y 4 , A, Q, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have the definitions as described for formula I as defined above, and preferred definitions of Y 1 , Y 2 , Y 3 , Y 4 , A, Q, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above; Hal stands for halogen.
  • Preferred individual compounds are:
  • the compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , A, T, Y 1 , Y 2 , Y 3 , and Y 4 , n, p and Q are as defined for formula I, can be obtained by transformation of a compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, T, Y 1 , Y 2 , Y 3 , and Y 4 , n, p and Q are as defined for formula I, with a compound of formula III, wherein R 8 and R 9 are as defined for formula I, and a peptide coupling reagent, such as BOP, PyBOP, HATU. This is shown in Scheme 1.
  • the compounds of formula II wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, T, Y 1 , Y 2 , Y 3 , and Y 4 , n, p and Q are as defined for formula I can be obtained by saponification of a compound of formula IV, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, T, Y 1 , Y 2 , Y 3 and Y 4 , n, p and Q are as defined for formula I and R 26 is C 1 -C 6 alkyl or optionally substituted aryl, with a base, such as potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, etc. This is shown in Scheme 2.
  • the compounds of formula V wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , A, Y 1 , Y 2 , Y 3 , and Y 4 , n, p and Q are as defined for formula I and R 26 is C 1 -C 6 alkyl or optionally substituted aryl, can be obtained by transformation of a compound of formula VI, wherein R 2 , R 3 , R 5 , R 6 , R 7 n, p and A are as defined for formula I and R 27 and R 28 are each independently hydroxy or C r C 6 alkyl or together with the interjacent boron atom form a five- or six-membered saturated heterocyclic ring, with a compound of formula VII, wherein Y 1 , Y 2 , Y 3 , and Y 4 and Q are as defined for formula I, R 26 is C 1 -C 6 alkyl or optionally substituted aryl and Hal is halogen, preferably i
  • the compounds of formula V wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , A, Y 1 , Y 2 , Y 3 , Y 4 , n, p and Q are as defined for formula I and R 26 is C 1 -C 6 alkyl or optionally substituted aryl, can be obtained by transformation of a compound of formula X, wherein R 2 , R 3 , R 4 , R 6 , R 7 A, Y 1 , Y 2 , Y 3 , Y 4 , n, p and Q are as defined for formula I and R 26 is C 1 -C 6 alkyl or optionally substituted aryl, with a compound of formula IX, wherein R 1 and A are as defined for formula I and R 29 is hydroxy or halogen, preferably, fluoro, chloro or bromo, and a peptide coupling reagent or a base, such as pyridine, triethy
  • the compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , A, T, Y 1 , Y 2 , Y 3 , Y 4 , n, p and Q are as defined for formula I can be obtained by transformation of a compound of formula XI, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, T, Y 1 , Y 2 , Y 3 , Y 4 , n, p and Q are as defined for formula I and Hal is halogen, preferably fluoro, chloro or bromo, with a compound of formula III, wherein R 8 and R 9 are as defined for formula I, with a base, such as pyridine, triethylamine, ethyl diisopropylamine etc. This is shown in Scheme 7.
  • novel compounds of formula I have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.
  • the compounds of formula I can be used in the agricultural sector and related fields of use e.g. as active ingredients for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmful to man.
  • the novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and may be used for protecting numerous cultivated plants.
  • the compounds of formula I can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.
  • compositions comprising a compound of formula I before planting: seed, for example, can be dressed before being sown.
  • the active ingredients according to the invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation.
  • the composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.
  • the compounds according to present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.
  • the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.
  • the compounds of formula I are, for example, effective against the phytopathogenic fungi of the following classes: Fungi imperfecti (e.g. Alternaria spp.), Basidiomycetes (e.g. Corticium spp., Ceratobasidium spp., Waitea spp., Thanatephorus spp., Rhizoctonia spp., Hemileia spp., Puccinia spp., Phakopsora spp., Ustilago spp., Tilletia spp.), Ascomycetes (e.g.
  • Venturia spp. Blumeria spp., Erysiphe spp., Podosphaera spp., Uncinula spp., Monilinia spp., Sclerotinia spp., Colletotrichum spp., Glomerella spp., Fusarium spp., Gibberella spp., Monographella spp., Phaeosphaeria spp., Mycosphaerella spp., Cercospora spp., Pyrenophora spp., Rhynchosporium spp., Magnaporthe spp., Gaeumannomyces spp., Oculimacula spp., Ramularia spp., Botryotinia spp.) and Oomycetes (e.g.
  • Phytophthora spp. Pythium spp., Plasmopara spp., Peronospora spp., Pseudoperonospora spp. Bremia spp).
  • Outstanding activity is observed against downy mildew (e.g. Plasmopara viticola ) and late blight (e.g. Phytophthora infestans ).
  • the novel compounds of formula I are effective against phytopathogenic gram negative and gram positive bacteria (e.g. Xanthomonas spp, Pseudomonas spp, Erwinia amylovora, Ralstonia spp.) and viruses (e.g. tobacco mosaic virus).
  • target crops and/or useful plants to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor)
  • the useful plants and/or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties.
  • suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties.
  • useful plants and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering.
  • herbicides like bromoxynil or classes of herbicides
  • EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors
  • GS glutamine synthetase
  • PPO protoporphyrinogen-oxidase
  • imazamox by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola).
  • crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.
  • useful plants and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.
  • useful plants and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called “pathogenesis-related proteins” (PRPs, see e.g. EP-A-0 392 225).
  • PRPs pathogenesis-related proteins
  • Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818, and EP-A-0 353 191.
  • the methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
  • locus of a plant as used herein is intended to embrace the place on which the plants are growing, where the plant propagation materials of the plants are sown or where the plant propagation materials of the plants will be placed into the soil.
  • An example for such a locus is a field, on which crop plants are growing.
  • plant propagation material is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably “plant propagation material” is understood to denote seeds.
  • the compounds of formula I may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.
  • Suitable carriers and adjuvants can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers.
  • Such carriers are for example described in WO 97/33890.
  • the compounds of formula I may be used in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.
  • further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.
  • the compounds of formula I are normally used in the form of fungicidal compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula I or of at least one preferred individual compound as above-defined, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants
  • the invention provides a fungicidal composition
  • a fungicidal composition comprising at least one compound formula I, an agriculturally acceptable carrier and optionally an adjuvant.
  • An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use.
  • Agricultural carriers are well known in the art.
  • said fungicidal compositions may comprise an additional fungicidal active ingredient in addition to the compound of formula I.
  • the compound of formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as an insecticide, fungicide, synergist, herbicide or plant growth regulator where appropriate.
  • An additional active ingredient may, in some cases, result in unexpected synergistic activities.
  • suitable additional active ingredients include the following: Azoxystrobin (131860-33-8), Dimoxystrobin (149961-52-4), Enestrobin (238410-11-2), Fluoxastrobin (193740-76-0), Kresoxim-methyl (143390-89-0), Metominostrobin (133408-50-1), Orysastrobin (248593-16-0), Picoxystrobin (117428-22-5), Pyraclostrobin (175013-18-0), Azaconazole (60207-31-0), Bromuconazole (116255-48-2), Cyproconazole (94361-06-5), Difenoconazole (119446-68-3), Diniconazole (83657-24-3), Diniconazole-M (83657-18-5), Epoxiconazole (13385-98-8), Fenbuconazole (114369-43-6), Fluquinconazole (136426-54-5), Flusilazole (85509-19-9), Flutriafol (76674-21-0), Hexa
  • Another aspect of invention is related to the use of a compound of formula I or of a preferred individual compound as above-defined, of a composition comprising at least one compound of formula I or at least one preferred individual compound as above-defined, or of a fungicidal mixture comprising at least one compound of formula I or at least one preferred individual compound as above-defined, in admixture with other fungicides, as described above, for controlling or preventing infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by phytopathogenic microorganisms, preferably fungal organisms.
  • useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by phytopathogenic microorganisms, preferably fungal organisms.
  • a further aspect of invention is related to a method of controlling or preventing an infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of formula I or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials.
  • Controlling or preventing means reducing infestation by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.
  • a preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a compound of formula I, or an agrochemical composition which contains at least one of said compounds, is foliar application.
  • the frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen.
  • the compounds of formula I can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field.
  • the compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.
  • a formulation e.g. a composition containing the compound of formula I, and, if desired, a solid or liquid adjuvant or monomers for encapsulating the compound of formula I, may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • extenders for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • the agrochemical formulations and/or compositions will usually contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of the compound of formula I, 99.9 to 1% by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant.
  • Advantageous rates of application are normally from 5 g to 2 kg of active ingredient (a.i.) per hectare (ha), preferably from 10 g to 1 kg a.i./ha, most preferably from 20 g to 600 g a.i./ha.
  • convenient dosages are from 10 mg to 1 g of active substance per kg of seeds.
  • Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester can be prepared according to the following reference: Eastwood, P. R. Tetrahedron Letters 2000, 41, 3705 or purchased from suitable supplier (CAS 286961-14-6).
  • Methyl-((R)-1-phenyl-ethyl)-amine (0.132 g, 0.80 mmol) was added to the reaction mixture.
  • solvent was evaporated and the resulting brown oil was dissolved in ethylacetate (20 mL), washed with aq. sat. sodium bicarbonate solution (30 mL) and the aqueous phase was re-extracted with ethylacetate (20 mL).
  • the combined organic layers were washed with 1M HCl solution (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure.
  • Table 1 illustrates examples of individual compounds of formula I according to the invention.
  • LC/MS Liquid Chromatography Mass Spectroscopy and the description of the apparatus and the method is: (HP 1100 HPLC from Agilent, Phenomenex Gemini C18, 3 ⁇ m particle size, 110 Angström, 30 ⁇ 3 mm column, 1.7 mL/min., 60° C., H 2 O+0.05% HCOOH (95%)/CH 3 CN/MeOH 4:1+0.04% HCOOH (5%) ⁇ 2 min. ⁇ CH 3 CN/MeOH 4:1+0.04% HCOOH (5%) ⁇ 0.8 min., ZQ Mass Spectrometer from Waters, ionization method: electrospray (ESI), Polarity: positive ions, Capillary (kV) 3.00, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (° C.) 100, Desolvation Temperature (° C.) 250, Cone Gas Flow (L/Hr) 50, De
  • Tomato leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water.
  • the leaf disks are inoculated with a spore suspension of the fungus 1 day after application.
  • the inoculated leaf disks are incubated at 16° C. and 75% rh under a light regime of 24 h darkness followed by 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5-7 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.011, I.n.049, I.n.097, I.t.001, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • 2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the test plants are inoculated by spraying them with a sporangia suspension 2 days after application.
  • the inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (5-7 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.049, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • 2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the test plants are inoculated by spraying them with a sporangia suspension 6 days after application.
  • the inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (9-11 days after application).
  • 2-week old potato plants cv. Bintje are inoculated by spraying them with a sporangia suspension one day before application.
  • the inoculated plants are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (3-4 days after application).
  • Grape vine leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water.
  • the leaf disks are inoculated with a spore suspension of the fungus 1 day after application.
  • the inoculated leaf disks are incubated at 19° C. and 80% rh under a light regime of 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6-8 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.009, I.n.011, I.n.049, I.n.097, I.t.001, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • 5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the test plants plants are inoculated by spraying a sporangia suspension on their lower leaf surface one day after application.
  • the inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (6-8 days after application).
  • 5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the test plants are inoculated by spraying a sporangia suspension on their lower leaf surface 6 days after application.
  • the inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (11-13 days after application).
  • 5-week-old grape seedlings cv. Gutedel are inoculated by spraying a sporangia suspension on their lower leaf surface one day before application.
  • the inoculated grape plants are sprayed in a spray chamber with the formulated test compound diluted in water.
  • the inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (4-6 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.049, I.v.001 and I.z.001 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Abstract

The present invention relates to heterocyclic compounds of formula I which have microbiocidal activity, in particular fungicidal activity as well as methods of using the compounds of formula I to control microbes:
Figure US20130144064A1-20130606-C00001
  • wherein
  • A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, x-N(R14)—C(═O)—, x-N(R15)—C(═S)—, x-C(R16R17)—SO2— or x-N═C(R30)—, in each case x indicates the bond that is connected to R1;
  • T is CR18 or N;
  • Y1, Y2, Y3, and Y4 are independently CR19 or N;
  • Q is O or S;
  • n is 1 or 2;
  • p is 1 or 2, providing that when n is 2, p is 1.
  • R1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
  • R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18, R19 and R30 each independently are hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl;
  • R8, R14 and R15 each independently are hydrogen or C1-C4alkyl; and
  • R9 is phenyl, benzyl or group (a):
Figure US20130144064A1-20130606-C00002
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
  • or a salt or a N-oxide thereof.

Description

  • This application is a divisional of U.S. Ser. No. 13/390,023, filed on Feb. 10, 2012, which is a 371 of International Application No. PCT/EP2010/061464 filed Aug. 6, 2010, which claims priority from 09167741.9 filed Aug. 12, 2009; the contents of all above-named applications are incorporated herein by reference.
  • The present invention relates to heterocycles, e.g. as active ingredients, which have microbiocidal activity, in particular fungicidal activity. The invention also relates to preparation of these heterocycles, to heterocyclic derivatives used as intermediates in the preparation of these heterocycles, to preparation of these intermediates, to agrochemical compositions which comprise at least one of the heterocycles, to preparation of these compositions and to use of the heterocycles or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.
  • Certain heterocycles for use as fungicides are described in WO 2007/014290, WO 2008/013622, WO 2008/013925, WO 2008/091580, WO 2008/091594 and WO 2009/055514.
  • The present invention provides compounds of formula I:
  • Figure US20130144064A1-20130606-C00003
  • wherein
    A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, x-N(R14)—C(═O)—, x-N(R15)—C(═S)—, x-C(R18R17)—SO2— or x-N═C(R30)— in each case x indicates the bond that is connected to R1;
    • T is CR18 or N;
  • Y1, Y2, Y3, and Y4 are independently CR19 or N;
    • Q is O or S;
  • n is 1 or 2;
    p is 1 or 2, providing that when n is 2, p is 1.
    R1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
    R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18, R19 and R30 each independently are hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl;
    R8, R14 and R15 each independently are hydrogen or C1-C4alkyl; and
    R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00004
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
    or a salt or a N-oxide thereof.
  • Where substituents are indicated as being optionally substituted, this means that they may or may not carry one or more identical or different substituents. Normally not more than three such optional substituents are present at the same time.
  • The term “halogen” stands for fluorine, chlorine, bromine or iodine.
  • The term “amino” stands for —NH2.
  • Alkyl, alkenyl or alkynyl substituents may be straight-chained or branched. Alkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl and the isomers thereof, for example, iso-propyl, iso-butyl, sec-butyl, tert-butyl, iso-amyl or pivaloyl.
  • A haloalkyl group may contain one or more identical or different halogen atoms and, for example, may stand for CH2Cl1, CHCl2, CCl3, CH2F, CHF2, CF3, CF3CH2, CH3CF2, CF3CF2 or CCl3CCl2.
  • The presence of one or more possible asymmetric carbon atoms in a compound of formula I means that the compounds may occur in optically isomeric froms, i.e. enantiomeric or diastereomeric forms. As a result of the presence of a possible aliphatic C═C double bond, geometric isomerism may occur, i.e. cis-trans or (E)-(Z) isomerism. Also atropisomers may occur as a result of restricted rotation about a single bond. Formula I is intended to include all those possible isomeric forms and mixtures thereof. The present invention includes all those possible isomeric forms and mixtures thereof for a compound of formula I. Likewise, formula I is intended to include all possible tautomers. The present invention includes all possible tautomeric forms for a compound of formula I.
  • In each case, the compounds of formula I according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.
  • N-oxides are oxidized forms of teriary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.
  • Suitable salts of the compounds of formula I include those resulting after addition of acid such as those with an inorganic mineral acid e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid, or an organic carboxylic acid e.g. oxalic, tartaric, lactic, butyric, toluic, hexanoic or phthalic acid, or a sulfonic acid e.g. methane, benzene or toluene sulfonic acid.
  • Preferably the compound of formula I is a compound wherein:
  • A is x-C(R19R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, x-N(R14)—C(═O)—, x-N(R15)—C(═S)— or x-C(R16R17)—SO2—, in each case x indicates the bond that is connected to R1;
    • T is CR18 or N;
  • Y1, Y2, Y3, and Y4 are independently CR19 or N;
    • Q is O or S;
  • n is 1 or 2;
    p is 1 or 2, providing that when n is 2, p is 1.
    R1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
    R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18 and R19 each independently are hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl;
    R8, R14 and R15 each independently are hydrogen or C1-C4alkyl; and
    R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00005
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino;
    or a salt or a N-oxide thereof.
  • Preferably the compound of formula I is a compound wherein:
  • A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, or x-C(R16R17)—SO2—, in each case x indicates the bond that is connected to R1;
    • T is CR18 or N;
  • Y1, Y2, Y3, and Y4 are independently CR19 or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CR19;
    • Q is O or S;
  • n is 1 or 2;
    p is 1;
    R1 is phenyl or pyrazolyl; wherein the phenyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy, and amino;
    R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18, and R19 each independently are hydrogen, halogen, C1-C4alkyl, C1-C4haloalkyl;
    R8 is hydrogen or C1-C4alkyl; and
    R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00006
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino.
  • Preferably the compound of formula I is a compound wherein:
  • A is x-CR10R11—C(═O)—, x-O—C(═O)—, or x-CR16R17—SO2—, in each case x indicates the bond that is connected to R1;
    • T is CR19;
  • Y1, Y2, Y3, and Y4 are independently CR19 or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CR19 and providing that there are no N—N bonds in the ring containing Y1, Y2, Y3, and Y4;
    • Q is O or S;
  • n is 1 or 2;
    p is 1;
    R1 is phenyl or pyrazolyl, wherein the phenyl and pyrazolyl are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, and halogen;
    R2, R3, R4, R5, R6, R7, R10, R11, R16, R17, R18, and R19 each independently are hydrogen, fluoro, or methyl;
    R8 is hydrogen or methyl; and
    R9 is phenyl, benzyl or group (a)
  • Figure US20130144064A1-20130606-C00007
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxy and halogen.
  • Preferably the compound of formula I is a compound wherein:
  • A is x-CH2—C(═O)—, x-O—C(═O)— or x-CH2—SO2—, in each case x indicates the bond that is connected to R1;
    • T is CH;
  • Y1, Y2, Y3, and Y4 are independently CH or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CH and providing that there are no N—N bonds in the ring containing Y1, Y2, Y3, and Y4;
    • Q is O;
  • n is 1 or 2;
    p is 1;
    R1 is phenyl or group (b)
  • Figure US20130144064A1-20130606-C00008
  • wherein the phenyl and group (b) are each optionally substituted with 1 to 3 substituents independently selected from halogen, C1-C4 alkyl and C1-C4 haloalkyl;
    R2, R3, R4, R5, R6 and R7 are each hydrogen;
    R8 is hydrogen or methyl; and
    R9 is phenyl, benzyl or group (a)
  • Figure US20130144064A1-20130606-C00009
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxy and halogen.
  • Preferably the compound of formula I is a compound wherein:
  • A is x-CH2—C(═O)—, wherein x indicates the bond that is connected to R1;
    • T is CH;
  • Y1, Y2, Y3, and Y4 are independently CH;
    • Q is O;
  • n is 2;
    p is 1;
    R1 is selected from group (c) or (d):
  • Figure US20130144064A1-20130606-C00010
  • wherein R22, R23, R24 and R25 are independently selected from hydrogen, halogen, methyl and halomethyl;
    R2, R3, R4, R5, R6, and R7 are each hydrogen;
    R8 is hydrogen or methyl; and
    R9 is phenyl, benzyl or group (a)
  • Figure US20130144064A1-20130606-C00011
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from methyl, halomethyl, and halogen.
  • The invention also relates to compounds of formula I wherein
  • A is x-CH2—C(═O)—, x-CH2C(═S)—, x-OC(═O)—, x-CH2SO2—, in each case x being the bond to R1;
    • T is CH or N;
  • Y1, Y2, Y3, and Y4 are independently CH or N, providing that at least 2 of Y1, Y2, Y3, and Y4 are CH and providing that there are no N—N bonds in the ring containing Y1, Y2, Y3;
    • Q is O or S;
  • n is 1 or 2;
    p is 1 or 2, providing that when n is 2, p is 1;
    R1 is group (e), (f), (g), or (h):
  • Figure US20130144064A1-20130606-C00012
  • R2, R3, R4, R5, R6 and R7 are each hydrogen;
    R8 is hydrogen or methyl;
    R9 is group (i), (j), or (k):
  • Figure US20130144064A1-20130606-C00013
  • The following list provides definitions, including preferred definitions, for substituents A, T, Y1, Y2, Y3, Y4, Q n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R22, R23, R24, R25 and R30 with reference to compounds of formula I. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below. The invention includes compounds of formula having all possible combinations of substituent definitions given below or elsewhere in this document. Generally, in this document any substituent definition may be combined with any other substituent definition.
  • A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, x-N(R14)—C(═O)—, x-N(R15)—C(═S)— or x-C(R16R17)—SO2—, in each case x indicates the bond that is connected to R1. Preferably, A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, or x-C(R16R17)—SO2—, in each case x indicates the bond that is connected to R1. More preferably, A is x-CR10R11—C(═O)—, x-O—C(═O)—, or x-CR16R17—SO2—, in each case x indicates the bond that is connected to R1. Even more preferably, A is x-CH2—C(═O)—, x-CH2C(═S)—, x-OC(═O)—, x-CH2SO2—, in each case x indicates the bond that is connected to R1. Yet more preferably, A is x-CH2—C(═O)—, x-O—C(═O)— or x-CH2—SO2—, in each case x indicates the bond that is connected to R1. Most preferably, A is x-CH2—C(═O)—, wherein x indicates the bond that is connected to R1.
  • T is CR18 or N. Preferably, T is CH or N. Most preferably, T is CH.
  • n is 1 or 2. Preferably, n is 2.
  • p is 1 or 2, providing that when n is 2, p is 1. Preferably, p is 1.
  • Y1, Y2, Y3, and Y4 are independently CR19 or N, e.g. Y1, Y2, Y3, and Y4 may be independently CH or N. More preferably, Y1, Y2, Y3, and Y4 are independently CR19 or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CR19. Even more preferably, Y1, Y2, Y3, and Y4 are independently CR19 or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CR19 and providing that there are no N—N bonds in the ring containing Y1, Y2, Y3, and Y4. Yet more preferably, Y1, Y2, Y3, and Y4 are independently CH or N providing that at least 2 of Y1, Y2, Y3, and Y4 are CH and providing that there are no N—N bonds in the ring containing Y1, Y2, Y3, and Y4.
    • Q is O or S. Preferably, Q is O.
  • R1 is phenyl, pyridyl, imidazolyl, or pyrazolyl; wherein the phenyl, pyridyl, imidazolyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino. Preferably, R1 is phenyl or pyrazolyl; wherein the phenyl and pyrazolyl are each optionally substituted by 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy, and amino. More preferably, R1 is phenyl or pyrazolyl, wherein the phenyl and pyrazolyl are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, and halogen. Yet more preferably, R1 is phenyl or group (b):
  • Figure US20130144064A1-20130606-C00014
  • wherein the phenyl and group (b) are each optionally substituted with 1 to 3 substituents independently selected from halogen, C1-C4 alkyl and C1-C4 haloalkyl. Even more preferably, R1 is phenyl or group (b):
  • Figure US20130144064A1-20130606-C00015
  • wherein the phenyl and group (b) are each optionally substituted with 1 to 3 substituents independently selected from halogen, methyl and halomethyl.
  • In one group of compounds R1 is selected from group (c) or (d):
  • Figure US20130144064A1-20130606-C00016
  • wherein R22, R23, R24 and R25 are independently selected from hydrogen, halogen, methyl and halomethyl.
  • In one group of compounds R1 is group (e), (f), (g), or (h):
  • Figure US20130144064A1-20130606-C00017
  • R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18 and R19 each independently are hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl. More preferably, R2, R3, R4, R5, R6, R7, R10, R11, R12, R13, R16, R17, R18, and R19 each independently are hydrogen, halogen, C1-C4alkyl, C1-C4haloalkyl. Even more preferably, R2, R3, R4, R5, R6, R7, R10, R11, R16, R17, R18, and R19 each independently are hydrogen, fluoro, or methyl. Yet more preferably, R2, R3, R4, R5, R6, R7, R10, R11, R16, R17, R18, and R19 each are hydrogen.
  • R8, R14 and R15 each independently are hydrogen or C1-C4alkyl. Preferably, R8, R14 and R15 each independently are hydrogen or methyl. Preferably, R8, R14 and R15 each are hydrogen.
  • R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00018
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, halogen, cyano, hydroxy and amino. Preferably, R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00019
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxy and halogen. More preferably, R9 is phenyl, benzyl or group (a):
  • Figure US20130144064A1-20130606-C00020
  • wherein the phenyl, benzyl and group (a) are each optionally substituted with 1 to 3 substituents independently selected from methyl, halomethyl, and halogen.
  • In one group of compounds R9 is (i), (j), or (k):
  • Figure US20130144064A1-20130606-C00021
  • Preferably, R22 is hydrogen or CF3. Preferably, R23, R24, and R25 are independently hydrogen or methyl.
  • R30 is hydrogen, halogen, cyano, C1-C4alkyl, or C1-C4haloalkyl. Preferably, R30 is hydrogen, halogen, C1-C4alkyl, or C1-C4haloalkyl. Preferably, R30 is hydrogen, fluoro, or methyl. More preferably, R30 is hydrogen.
  • In one group of compounds at least two of Y1, Y2, Y3 and Y4 are CH and the others of Y1, Y2, Y3 and Y4 are CH or N.
  • In one group of compounds at least three of Y1, Y2, Y3 and Y4 are CH and the other of Y1, Y2, Y3 and Y4 is CH or N.
  • In one group of compounds Y1 and Y4 are CH, one of Y2 and Y3 is CH and the other of Y2 and Y3 is CH or N.
  • In one group of compounds Y1, Y2 and Y4 are CH, and Y3 is N.
  • In one group of compounds Y1, Y3 and Y4 are CH, and Y2 is N.
  • In one group of compounds Y1, Y2, Y3 and Y4 are CH.
  • In one group of compounds Y2 is N.
  • In one group of compounds Y3 is N.
  • In one group of compounds p is 1 and n is 2.
  • In one group of compounds R2, R3, R4, R5, R6 and R7 are H.
  • In one group of compounds Q is O.
  • In one group of compounds A is x-CH2—C(═O)—, in which x represents the bond that is connected to R1.
  • In one group of compounds R1 is group (f)
  • Figure US20130144064A1-20130606-C00022
  • In one group of compounds R8 is hydrogen.
  • For the avoidance of doubt, when n is 1 and p is 1 compounds of formula I have the formula according to formula IA:
  • Figure US20130144064A1-20130606-C00023
  • in which A, T, Y1, Y2, Y3, Y4, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I.
  • When n is 2 and p is 1, compounds of formula I have the formula according to formula IB:
  • Figure US20130144064A1-20130606-C00024
  • in which A, T, G, Y1, Y2, Y3, Y4, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I.
  • When n is 1 and p is 2, compounds of formula I have the formula according to formula IC:
  • Figure US20130144064A1-20130606-C00025
  • in which A, T, G, Y1, Y2, Y3, Y4, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I.
  • The invention also relates to compounds of formula IA, formula IB, and formula IC as shown above.
  • The invention also relates to compounds of formula ID:
  • Figure US20130144064A1-20130606-C00026
  • wherein Y1, Y2, Y3, Y4, A, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I as defined above. Preferred definitions of Y1, Y2, Y3, Y4, A, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
  • The invention also relates to compounds of formula IE:
  • Figure US20130144064A1-20130606-C00027
  • wherein Y1, Y2, Y3, Y4, A, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I as defined above. Preferred definitions of Y1, Y2, Y3, Y4, A, Q, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined above.
  • The invention also relates to a compound of formula IF:
  • Figure US20130144064A1-20130606-C00028
  • wherein T is N or CH;
    Y2 and Y3 are both CH, or one of Y3 and Y2 is N and the other is CH; and
    R1 and R9 are as described for a compound of formula I as defined above. Preferred definitions of R1 and R9 are as as defined above
  • The invention also relates to a compound of formula IG:
  • Figure US20130144064A1-20130606-C00029
  • wherein T is N or CH;
    Y2 and Y3 are both CH, or one of Y3 and Y2 is N and the other is CH; and
    R9 is as described for a compound of formula I as defined above. Preferred definitions of R9 are as defined above.
  • The invention also includes compounds of formula I in which R1 is a protecting group, such as an alkyl group. Accordingly the invention includes compounds of formula I.a:
  • Figure US20130144064A1-20130606-C00030
  • wherein R1′ is C1-C8 alkyl, e.g. C1-C4 alkyl, preferably tert-butyl, and Y1, Y2, Y3, Y4, A, Q, T, n, p, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I as defined above. Preferred definitions of Y1, Y2, Y3, Y4, A, Q, T, n, p, R2, R3, R4, R5, R6, R7, R8, and R9 areas defined above.
  • The invention also relates to other intermediates useful in the preparation of compounds of formula I. Accordingly, the invention relates to a compound of formula II:
  • Figure US20130144064A1-20130606-C00031
  • wherein Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7 have the definitions as described for formula I as defined above. Preferred definitions of Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7 are as defined above.
  • The invention relates to a compound of formula IV:
  • Figure US20130144064A1-20130606-C00032
  • wherein Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7, have the definitions as described for formula I as defined above, and preferred definitions of Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7 are as defined above; and R26 is C1-C6 alkyl or optionally substituted aryl. Preferably, R26 is C1-C6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • The invention relates to a compound of formula V:
  • Figure US20130144064A1-20130606-C00033
  • wherein Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R6 and R7, have the definitions as described for formula I as defined above, and preferred definitions of Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R6 and R7 are as defined above; and R26 is C1-C6 alkyl or optionally substituted aryl. Preferably, R26 is C1-C6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • The invention relates to a compound of formula X:
  • Figure US20130144064A1-20130606-C00034
  • wherein Y1, Y2, Y3, Y4, Q, n, p, R2, R3, R4, R6 and R7 have the definitions as described for formula I as defined above, and preferred definitions of Y1, Y2, Y3, Y4, Q, n, p, R2, R3, R4, R6 and R7 are as defined above; and R26 is C1-C6 alkyl or optionally substituted aryl. Preferably, R26 is C1-C6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, amino, cyano and halogen.
  • The invention relates to a compound of formula XI:
  • Figure US20130144064A1-20130606-C00035
  • wherein Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R5, R6 and R7, have the definitions as described for formula I as defined above, and preferred definitions of Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R5, R6 and R7 are as defined above; Hal stands for halogen.
  • Preferred individual compounds are:
    • 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalene-1-yl-benzamide (Compound No. I.n.001);
    • 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—((R)-1-phenyl-ethyl)-benzamide (Compound No. I.n.003);
    • 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-(1,2,3,4-tetrahydro-naphthalene-1-yl)-benzamide (Compound No. I.n.005);
    • 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-(1-phenyl-ethyl)-benzamide (Compound No. I.n.007);
    • N-benzyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-benzamide (Compound No. I.n.009);
    • 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-phenyl-benzamide (Compound No. I.n.011);
    • 3-{1-[2-(2,5-Dimethyl-phenyl)-acetyl]-piperidin-4-yl}-N—(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide (Compound No. I.n.049);
    • 3-{1-[2-(3,5-Dimethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide (Compound No. I.n.097);
    • N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalene-1-yl-benzamide (Compound No. I.o.001);
    • N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—((R)-1-phenyl-ethyl)-benzamide (Compound No. I.o.003);
    • N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-(1,2,3,4-tetrahydro-naphthalene-1-yl)-benzamide (Compound No. I.o.005);
    • N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N-(1-phenyl-ethyl)-benzamide (Compound No. I.o.007);
    • 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid ((R)-1,2,3,4-tetrahydro-naphthalene-1-yl)amide (Compound No. 1.p.001);
    • 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl-6-carboxylic acid (1,2,3,4-tetrahydro-naphthalene-1-yl)-amide (Compound No. 1.p.005);
    • 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid (1-phenyl-ethyl)-amide (Compound No. 1.p.007);1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-5-carboxylic acid-(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)amide (Compound No. 1.t.001);
    • 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[4,4]bipyridinyl-2-carboxylic acid-(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (Compound No. 1.v.001);
    • 3-{4-[2-(3,5-Dimethyl-pyrazol-1-yl)-acetyl]piperazin-1-yl}-N—(R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide (Compound No. 1.z.001); and
    • 3-{4-[2-(3,5-Dimethyl-pyrazol-1-yl)-acetyl]piperazin-1-yl}-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzamide (Compound No. 1.z.005);
  • Compounds of formula (I) can be made as shown in the following schemes.
  • The compounds of formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, A, T, Y1, Y2, Y3, and Y4, n, p and Q are as defined for formula I, can be obtained by transformation of a compound of formula II, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3, and Y4, n, p and Q are as defined for formula I, with a compound of formula III, wherein R8 and R9 are as defined for formula I, and a peptide coupling reagent, such as BOP, PyBOP, HATU. This is shown in Scheme 1.
  • Figure US20130144064A1-20130606-C00036
  • The compounds of formula II, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3, and Y4, n, p and Q are as defined for formula I can be obtained by saponification of a compound of formula IV, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3 and Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, with a base, such as potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, etc. This is shown in Scheme 2.
  • Figure US20130144064A1-20130606-C00037
  • The compounds of formula IV.1, wherein R1, R2, R3, R4, R5, R6, R7, A, Y2, Y3, and Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, can be obtained by reduction of a compound of formula V, wherein R1, R2, R3, R4, R6, R7, A, Y2, Y3, and Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, and hydrogen with a catalyst, such as palladium on charcoal, raney-nickel, etc, or with lithium aluminum hydride. This is shown in Scheme 3.
  • Figure US20130144064A1-20130606-C00038
  • The compounds of formula V, wherein R1, R2, R3, R4, R6, R7, A, Y1, Y2, Y3, and Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, can be obtained by transformation of a compound of formula VI, wherein R2, R3, R5, R6, R7 n, p and A are as defined for formula I and R27 and R28 are each independently hydroxy or Cr C6alkyl or together with the interjacent boron atom form a five- or six-membered saturated heterocyclic ring, with a compound of formula VII, wherein Y1, Y2, Y3, and Y4 and Q are as defined for formula I, R26 is C1-C6alkyl or optionally substituted aryl and Hal is halogen, preferably iodo, bromo or chloro, and a catalyst. This is shown in Scheme 4.
  • Figure US20130144064A1-20130606-C00039
  • The compounds of formula VI, wherein R1, R2, R3, R4, R6, R7 n, p and A are as defined for formula I and R27 and R28 are each independently hydroxy or C1-C6alkyl or together with the interjacent boron atom form a five- or six-membered saturated heterocyclic ring, can be obtained by transformation of a compound of formula VIII, wherein R1, R2, R3, R4, R6, R7, n and p are as defined for formula I and R27 and R28 are each independently hydroxy or C1-C6alkyl or together with the interjacent boron atom form a five- or six-membered saturated heterocyclic ring, with a compound of formula IX, wherein R1 and A are as defined for formula I and R29 is hydroxy or halogen, preferably, fluoro, chloro or bromo, and a peptide coupling reagent or a base, such as pyridine, triethylamine, ethyl diisopropylamine etc. This is shown in Scheme 5.
  • Figure US20130144064A1-20130606-C00040
  • Alternatively, the compounds of formula V, wherein R1, R2, R3, R4, R6, R7, A, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, can be obtained by transformation of a compound of formula X, wherein R2, R3, R4, R6, R7 A, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, with a compound of formula IX, wherein R1 and A are as defined for formula I and R29 is hydroxy or halogen, preferably, fluoro, chloro or bromo, and a peptide coupling reagent or a base, such as pyridine, triethylamine, ethyl diisopropylamine etc. This is shown in Scheme 6.
  • Figure US20130144064A1-20130606-C00041
  • Alternatively, the compounds of formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, A, T, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I can be obtained by transformation of a compound of formula XI, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I and Hal is halogen, preferably fluoro, chloro or bromo, with a compound of formula III, wherein R8 and R9 are as defined for formula I, with a base, such as pyridine, triethylamine, ethyl diisopropylamine etc. This is shown in Scheme 7.
  • Figure US20130144064A1-20130606-C00042
  • The compounds of formula XI, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I and Hal is halogen, preferably fluoro, chloro or bromo, can be obtained by transformation of a compound of formula II, wherein R1, R2, R3, R4, R5, R6, R7, A, T, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I, with a phosphoryl halide, such as phosphoryl chloride or phosphoryl bromide, or a thionyl halide, such as thionyl chloride or thionyl bromide. This is shown in Scheme 8.
  • Figure US20130144064A1-20130606-C00043
  • The compounds of formula IV.2, wherein R1, R2, R3, R4, R5, R6, R7, A, Y1, Y2, Y3, Y4, n, p and Q are as defined for formula I and R26 is C1-C6alkyl or optionally substituted aryl, can be obtained by transformation of a compound of formula XII, wherein R1, R2, R3, R4, R6, R7 n, p and A are as defined for formula I, with a compound of formula VII, wherein Y1, Y2, Y3, Y4 and Q are as defined for formula I, R26 is C1-C6alkyl or optionally substituted aryl and Hal is halogen, preferably iodo, bromo or chloro. This is shown in Scheme 9.
  • Figure US20130144064A1-20130606-C00044
  • Surprisingly, it has now been found that the novel compounds of formula I have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.
  • The compounds of formula I can be used in the agricultural sector and related fields of use e.g. as active ingredients for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmful to man. The novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and may be used for protecting numerous cultivated plants. The compounds of formula I can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.
  • It is also possible to use compounds of formula I as dressing agents for the treatment of plant propagation material, e.g., seed, such as fruits, tubers or grains, or plant cuttings (for example rice), for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil. The propagation material can be treated with a composition comprising a compound of formula I before planting: seed, for example, can be dressed before being sown. The active ingredients according to the invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation. The composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.
  • Furthermore the compounds according to present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.
  • In addition, the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.
  • The compounds of formula I are, for example, effective against the phytopathogenic fungi of the following classes: Fungi imperfecti (e.g. Alternaria spp.), Basidiomycetes (e.g. Corticium spp., Ceratobasidium spp., Waitea spp., Thanatephorus spp., Rhizoctonia spp., Hemileia spp., Puccinia spp., Phakopsora spp., Ustilago spp., Tilletia spp.), Ascomycetes (e.g. Venturia spp., Blumeria spp., Erysiphe spp., Podosphaera spp., Uncinula spp., Monilinia spp., Sclerotinia spp., Colletotrichum spp., Glomerella spp., Fusarium spp., Gibberella spp., Monographella spp., Phaeosphaeria spp., Mycosphaerella spp., Cercospora spp., Pyrenophora spp., Rhynchosporium spp., Magnaporthe spp., Gaeumannomyces spp., Oculimacula spp., Ramularia spp., Botryotinia spp.) and Oomycetes (e.g. Phytophthora spp., Pythium spp., Plasmopara spp., Peronospora spp., Pseudoperonospora spp. Bremia spp). Outstanding activity is observed against downy mildew (e.g. Plasmopara viticola) and late blight (e.g. Phytophthora infestans). Furthermore, the novel compounds of formula I are effective against phytopathogenic gram negative and gram positive bacteria (e.g. Xanthomonas spp, Pseudomonas spp, Erwinia amylovora, Ralstonia spp.) and viruses (e.g. tobacco mosaic virus).
  • Within the scope of present invention, target crops and/or useful plants to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor) or plants such as tobacco, nuts, coffee, eggplants, sugar cane, tea, pepper, vines, hops, bananas and natural rubber plants, as well as turf and ornamentals.
  • The useful plants and/or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties. By way of example, suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties.
  • The term “useful plants” and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.
  • The term “useful plants” and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.
  • The term “useful plants” and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called “pathogenesis-related proteins” (PRPs, see e.g. EP-A-0 392 225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0 392 225, WO 95/33818, and EP-A-0 353 191. The methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
  • The term “locus” of a plant as used herein is intended to embrace the place on which the plants are growing, where the plant propagation materials of the plants are sown or where the plant propagation materials of the plants will be placed into the soil. An example for such a locus is a field, on which crop plants are growing.
  • The term “plant propagation material” is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably “plant propagation material” is understood to denote seeds.
  • The compounds of formula I may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.
  • Suitable carriers and adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.
  • The compounds of formula I may be used in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.
  • The compounds of formula I are normally used in the form of fungicidal compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula I or of at least one preferred individual compound as above-defined, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants
  • The invention provides a fungicidal composition comprising at least one compound formula I, an agriculturally acceptable carrier and optionally an adjuvant. An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural carriers are well known in the art. Preferably said fungicidal compositions may comprise an additional fungicidal active ingredient in addition to the compound of formula I.
  • The compound of formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as an insecticide, fungicide, synergist, herbicide or plant growth regulator where appropriate. An additional active ingredient may, in some cases, result in unexpected synergistic activities. Examples of suitable additional active ingredients include the following: Azoxystrobin (131860-33-8), Dimoxystrobin (149961-52-4), Enestrobin (238410-11-2), Fluoxastrobin (193740-76-0), Kresoxim-methyl (143390-89-0), Metominostrobin (133408-50-1), Orysastrobin (248593-16-0), Picoxystrobin (117428-22-5), Pyraclostrobin (175013-18-0), Azaconazole (60207-31-0), Bromuconazole (116255-48-2), Cyproconazole (94361-06-5), Difenoconazole (119446-68-3), Diniconazole (83657-24-3), Diniconazole-M (83657-18-5), Epoxiconazole (13385-98-8), Fenbuconazole (114369-43-6), Fluquinconazole (136426-54-5), Flusilazole (85509-19-9), Flutriafol (76674-21-0), Hexaconazole (79983-71-4), Imazalil (58594-72-2), Imibenconazole (86598-92-7), Ipconazole (125225-28-7), Metconazole (125116-23-6), Myclobutanil (88671-89-0), Oxpoconazole (174212-12-5), Pefurazoate (58011-68-0), Penconazole (66246-88-6), Prochloraz (67747-09-5), Propiconazole (60207-90-1), Prothioconazole (178928-70-6), Simeconazole (149508-90-7), Tebuconazole (107534-96-3), Tetraconazole (112281-77-3), Triadimefon (43121-43-3), Triadimenol (55219-65-3), Triflumizole (99387-89-0), Triticonazole (131983-72-7), Diclobutrazol (76738-62-0), Etaconazole (60207-93-4), Fluconazole (86386-73-4), Fluconazole-cis (112839-32-4), Thiabendazole (148-79-8), Quinconazole (103970-75-8), Fenpiclonil (74738-17-3), Fludioxonil (131341-86-1), Cyprodinil (121552-61-2), Mepanipyrim (110235-47-7), Pyrimethanil (53112-28-0), Aldimorph (91315-15-0), Dodemorph (1593-77-7), Fenpropimorph (67564-91-4), Tridemorph (81412-43-3), Fenpropidin (67306-00-7), Spiroxamine (118134-30-8), Isopyrazam (881685-58-1), Sedaxane (874967-67-6), Bixafen (581809-46-3), Penthiopyrad (183675-82-3), Fluxapyroxad (907204-31-3), Boscalid (188425-85-6), Penflufen (494793-67-8), Fluopyram (658066-35-4), Mandipropamid (374726-62-2), Benthiavalicarb (413615-35-7), Dimethomorph (110488-70-5), Chlorothalonil (1897-45-6), Fluazinam (79622-59-6), Dithianon (3347-22-6), Metrafenone (220899-03-6), Tricyclazole (41814-78-2), Mefenoxam (70630-17-0), Metalaxyl (57837-19-1), Acibenzolar (126448-41-7) (Acibenzolar-5-methyl (126448-41-7)), Mancozeb (8018-01-7), Ametoctradine (865318-97-4) Cyflufenamid (180409-60-3), Ipconazole (125225-28-7), Amisulbrom (348635-87-0), Ethaboxam (16650-77-3), Fluopicolide (239110-15-7), Fluthianil (304900-25-2), Isotianil (224049-04-1), Proquinazid (189278-12-4), Valiphenal (283159-90-0), 1-methyl-cyclopropene (3100-04-7), Trifloxystrobin (141517-21-7), Sulfur (7704-34-9), Copper ammoniumcarbonate (CAS 33113-08-5); Copper oleate (CAS 1120-44-1); Folpet (133-07-3), Quinoxyfen (124495-18-7), Captan (133-06-2), Fenhexamid (126833-17-8), Glufosinate and its salts (51276-47-2, 35597-44-5 (S-isomer)), Glyphosate (1071-83-6) and its salts (69254-40-6 (Diammonium), 34494-04-7 (Dimethylammonium), 38641-94-0 (Isopropylammonium), 40465-66-5 (Monoammonium), 70901-20-1 (Potassium), 70393-85-0 (Sesquisodium), 81591-81-3 (Trimesium)), 1,3-Dimethyl-1H-pyrazole-4-carboxylic acid (2-dichloromethylene-3-ethyl-1-methyl-indan-4-yl)-amide, 1,3-Dimethyl-1H-pyrazole-4-carboxylic acid (4′-methylsulfanyl-biphenyl-2-yl)-amide, 1,3-Dimethyl-4H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-2-methoxy-1-methyl-ethyl]-amide, (5-Chloro-2,4-dimethyl-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, (5-Bromo-4-chloro-2-methoxy-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, 2-{2-[(E)-3-(2,6-Dichloro-phenyl)-1-methyl-prop-2-en-(E)-ylideneaminooxymethyl]-phenyl}-2-[(Z)-methoxyimino]-N-methyl-acetamide, 3-[5-(4-Chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine.
  • Another aspect of invention is related to the use of a compound of formula I or of a preferred individual compound as above-defined, of a composition comprising at least one compound of formula I or at least one preferred individual compound as above-defined, or of a fungicidal mixture comprising at least one compound of formula I or at least one preferred individual compound as above-defined, in admixture with other fungicides, as described above, for controlling or preventing infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by phytopathogenic microorganisms, preferably fungal organisms.
  • A further aspect of invention is related to a method of controlling or preventing an infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of formula I or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials.
  • Controlling or preventing means reducing infestation by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.
  • A preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a compound of formula I, or an agrochemical composition which contains at least one of said compounds, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen. However, the compounds of formula I can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.
  • A formulation, e.g. a composition containing the compound of formula I, and, if desired, a solid or liquid adjuvant or monomers for encapsulating the compound of formula I, may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • The agrochemical formulations and/or compositions will usually contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of the compound of formula I, 99.9 to 1% by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant.
  • Advantageous rates of application are normally from 5 g to 2 kg of active ingredient (a.i.) per hectare (ha), preferably from 10 g to 1 kg a.i./ha, most preferably from 20 g to 600 g a.i./ha. When used as seed drenching agent, convenient dosages are from 10 mg to 1 g of active substance per kg of seeds.
  • Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations.
  • The following non-limiting examples illustrate the above-described invention in more detail.
    • EXAMPLE 1 This Example Illustrates the Preparation of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (Compound No. I.n.001)
  • a) Preparation of 4-(3-ethoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester1 1 3-Piperidin-4-yl-benzoic acid ethyl ester can also be prepared according to the following reference WO 2004092124 A2 20041028 (Merck & Co., Inc., USA).
  • To a solution of ethyl-3-iodobenzoate (10 g, 36.2 mmol) in dioxane (400 mL) were added successively bistriphenylphosphinpalladiumllchloride (1.26 g, 1.8 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester2 (13.44 g, 43.46 mmol), and aq. sol. sodium carbonate (11.5 g in 100 mL of water, 108.6 mmol) at RT. After stirring for 3 h at 110° C., solvent was evaporated and the resulting yellow oil was dissolved in ethylacetate (300 mL), washed with brine (300 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/heptane 0:1 to 3:7) to give 4-(3-ethoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (11.28 g, 94%). 1H-NMR (400 MHz, CDCl3): δ=1.39-1.43 (t, 3H), 1.53 (s, 9H), 2.55-2.59 (m, 2H), 3.64 (t, 2H), 4.17-4.22 (m, 2H), 4.35-4.42 (q, 2H), 6.12 (m, 1H), 7.39-7.43 (t, 1H), 7.55-7.58 (m, 1H), 7.91-7.94 (m, 1H), 8.05 (s, 1H). MS: m/z=332 (M+1). 2 Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester can be prepared according to the following reference: Eastwood, P. R. Tetrahedron Letters 2000, 41, 3705 or purchased from suitable supplier (CAS 286961-14-6).
    • b) Preparation of 4-(3-ethoxycarbonyl-phenyl)piperidine-1-carboxylic acid tert-butyl ester1
  • A solution of 4-(3-ethoxycarbonyl-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (11.28 g, 34.035 mmol) in ethanol (680 mL) was pumped through Pd/C cartridge using H-Cube apparatus (20° C., 10 bar, 2 mL/min.). The solvent was then evaporated under reduced pressure to give 4-(3-ethoxycarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (10.55 g, 93%), which can be used in the next step without further purification. 1H-NMR (400 MHz, CDCl3): δ=1.39-1.43 (t, 3H), 1.51 (s, 9H), 1.61-1.72 (dq, 1H), 1.78-1.90 (m, 1H), 2.66-2.74 (dt, 1H), 2.74-2.89 (m, 1H), 4.20-4.31 (m, 1H), 4.32-4.42 (q, 2H), 7.39-7.41 (m, 2H), 7.88-7.92 (m, 2H). MS: m/z=334 (M+1).
    • c) Preparation of 3-piperidin-4-yl-benzoic acid ethyl ester hydrochloride salt1
  • To a solution of 4-(3-ethoxycarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (10.55 g, 31.64 mmol) was added a solution of 4M HCl in dioxane (79 mL, 316.41 mmol)) at RT. After stirring overnight at RT, the solvent was evaporated under reduce pressure. The resulting yellowish viscous oil was triturated with diethylether, and filtered to give 3-piperidin-4-yl-benzoic acid ethyl ester hydrochloride salt (8.53 g, quant.). 1H-NMR (400 MHz, d6-DMSO): δ=1.81-1.86 (t, 3H), 1.91-1.98 (m, 3H), 2.50-2.52 (m, 1H (overlap with DMSO), 2.95-3.05 (m, 2H), 3.32-3.39 (m, 2H), 4.31-4.39 (q, 2H), 7.49-7.52 (m, 2H), 7.81-7.83 (m, 2H), 9.5 (br, 2H). MS: m/z=234 ((M-HCl)+1).
    • d) Preparation of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid ethyl ester
  • To a solution of (5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid (5.23 g, 20.75 mmol) in DMF (50 mL) was added diisopropylethylamine (43 mL, 207.58 mmol), followed by 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (10.52 g, 22.83 mmol) at RT. After stirring 15 min. at RT, 3-piperidin-4-yl-benzoic acid ethyl ester hydrochloride salt (5.6 g, 20.75 mmol) was added to the reaction mixture. After stirring overnight at RT, solvent was evaporated and the resulting brown oil was dissolved in ethylacetate (200 mL), washed with aq. sat. sodium bicarbonate solution (100 mL) and the aqueous phase was re-extracted with ethylacetate (200 mL). The combined organic layers were washed with 1M HCl solution (400 mL) and brine (400 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 0:1 to 1:1) to give 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid ethyl ester (4.35 g, 49.5%). 1H-NMR (400 MHz, d6-DMSO): δ=1.28-1.39 (t, 3H), 1.45-1.55 (m, 1H), 1.65-1.1.79 (m, 1H), 1.80-1.91 (m, 2H), 2.22 (s, 3H), 2.68-2.73 (m, 1H), 2.89-2.95 (m, 1H), 3.99-4.04 (m, 1H), 4.29-4.33 (q, 2H), 4.46-4.52 (m, 1H), 5.21-5.38 (dd, 2H, diastereotopic), 6.50 (s, 1H), 7.47 (t, 1H), 7.55 (d, 1H), 7.80 (s, 1H), 7.81 (d, 1H). MS: m/z=424 (M+1).
    • e) Preparation of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid
  • To a solution of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid ethyl ester (4.35 g, 10.27 mmol) in methanol (50 mL) was added aq. solution of sodium hydroxide (2 M, 7.7 mL, 15.41 mmol) at RT. After stirring 4 h at RT, the solvent was removed, and the residue was dissolved in THF (30 mL), and aq. solution of lithium hydroxide (121 mg in 5 mL of water) was added at RT. After stirring overnight at RT, the solvent was removed and the residue was dissolved in ethylacetate (50 mL) and the reaction mixture was acidified with 2M aq. solution of HCl until pH 1-2. After separation of phases, the aq. layer was re-extracted with ethylacetate (20 mL), and the combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure to give 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]piperidin-4-yl}-benzoic acid (2.40 g, 59%), which can be used in the next step without further purification. 1H-NMR (400 MHz, d6-DMSO): δ=1.45-1.55 (m, 1H), 1.65-1.1.79 (m, 1H), 1.80-1.91 (m, 2H), 2.22 (s, 3H), 2.67-2.78 (m, 1H), 2.89-2.95 (m, 1H), 3.17-3.24 (m, 1H), 3.95-4.04 (m, 1H), 4.46-4.52 (m, 1H), 5.21-5.38 (dd, 2H, diastereotopic), 6.50 (s, 1H), 7.47 (t, 1H), 7.55 (d, 1H), 7.80 (s, 1H), 7.81 (d, 1H). MS: m/z=396 (M+1).
    • f) Preparation of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (Compound No. I.n.001)
  • To a solution of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid (100 mg, 0.25 mmol) in DMF (2 mL) was added diisopropylethylamine (0.16 mL, 0.76 mmol), followed by 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (0.128 g, 0.27 mmol) at RT. After stirring 15 min. at RT, (R)-(1,2,3,4-tetrahydro-naphthalen-1-yl)amine (0.045 g, 0.25 mmol) was added to the reaction mixture. After stirring 2 h at RT, solvent was evaporated and the resulting brown oil was dissolved in ethylacetate (10 mL), washed with aq. sat. sodium bicarbonate solution (20 mL) and the aqueous phase was re-extracted with ethylacetate (20 mL). The combined organic layers were washed with 1M HCl solution (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 1:1 to 8:2) to give 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (125 mg, 94%). 1H-NMR (400 MHz, d6-DMSO): δ=1.52-1.61 (m, 1H), 1.68-1.89 (m, 5H), 1.91-2.02 (m, 1H), 2.22 (s, 3H), 2.64-2.92 (m, 4H), 3.15-3.24 (m, 1H), 3.99-4.04 (m, 1H), 4.46-4.52 (m, 1H), 5.19-5.38 (m, 3H), 6.50 (s, 1H), 7.12-7.19 (m, 4H), 7.38 (d, 1H), 7.75 (d, 1H), 7.82 (s, 1H), 8.71 (d, 1H). MS: m/z=525 (M+1).
    • EXAMPLE 2 This Example Illustrates the Preparation of N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (Compound No. I.o.001) a) Preparation of N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (Compound No. I.o.001)
  • To a solution of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid (320 mg, 0.80 mmol) in DMF (8 mL) was added diisopropylethylamine (1.01 mL, 4.85 mmol), followed by 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (0.41 g, 0.89 mmol) at RT. After stirring 15 min. at RT, methyl-(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-amine (0.158 g, 0.80 mmol) was added to the reaction mixture. After stirring for 2 h at RT, solvent was evaporated and the resulting brown oil was dissolved in ethylacetate (20 mL), washed with aq. sat. sodium bicarbonate solution (30 mL) and the aqueous phase was re-extracted with ethylacetate (20 mL). The combined organic layers were washed with 1M HCl solution (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 1:1 to 8:2) to give N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-benzamide (200 mg, 46%). 1H-NMR (400 MHz, d6-DMSO): δ=1.45-1.59 (m, 1H), 1.63-1.91 (m, 5H), 1.91-2.02 (m, 1H), 2.22 (s, 3H), 2.61 (s, 3H), 2.64-2.92 (m, 4H), 3.15-3.24 (m, 1H), 3.99-4.04 (m, 1H), 4.46-4.52 (m, 1H), 5.19-5.38 (m, 2H), 5.74-5.81 (m, 1H), 6.50 (s, 1H), 7.12-7.23 (m, 4H), 7.28-7.47 (m, 4H). MS: m/z=539 (M+1).
    • EXAMPLE 3 This Example Illustrates the Preparation of N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—((R)-1-phenyl-ethyl)-benzamide (Compound No. I.o.003) a) Preparation of N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—((R)-1-phenyl-ethyl)-benzamide (Compound No. I.o.003)
  • To a solution of 3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-benzoic acid (320 mg, 0.80 mmol) in DMF (8 mL) was added diisopropylethylamine (1.01 mL, 4.85 mmol), followed by 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (0.41 g, 0.89 mmol) at RT. After stirring for 15 min. at RT, Methyl-((R)-1-phenyl-ethyl)-amine (0.132 g, 0.80 mmol) was added to the reaction mixture. After stirring for 2 h at RT, solvent was evaporated and the resulting brown oil was dissolved in ethylacetate (20 mL), washed with aq. sat. sodium bicarbonate solution (30 mL) and the aqueous phase was re-extracted with ethylacetate (20 mL). The combined organic layers were washed with 1M HCl solution (50 mL) and brine (50 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 1:1 to 8:2) to give N-methyl-3-{1-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-piperidin-4-yl}-N—((R)-1-phenyl-ethyl)-benzamide (170 mg, 41%). 1H-NMR (400 MHz, d6-DMSO): δ=1.55 (d, 3H), 1.62-1.71 (m, 1H), 1.82-1.89 (m, 2H), 1.99 (s, 3H), 2.22 (s, 3H), 2.54-2.73 (m, 3H), 2.81-2.90 (m, 1H), 3.12-3.21 (m, 1H), 3.99-4.04 (m, 1H), 4.46-4.52 (m, 1H), 5.19-5.38 (m, 2H), 6.50 (s, 1H), 7.12-7.41 (m, 9H). MS: m/z=513 (M+1)
    • EXAMPLE 4 This Example Illustrates the Preparation of 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (Compound No. I.q.005) a) Preparation of 3′,6′-dihydro-2′H-[2,4′]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester
  • To a solution of 6-bromo-pyridine-2-carboxylic acid ethyl ester (1 g, 4.35 mmol) in dioxane (40 mL) were added successively bistriphenylphosphinpalladiumllchloride (0.152 g, 0.217 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester2 (1.61 g, 5.21 mmol), and aq. sol. sodium carbonate (1.38 g in 10 mL of water, 13.04 mmol) at RT. After stirring 3 h at 110° C., solvent was evaporated and the resulting yellow oil was dissolved in ethylacetate (30 mL), washed with brine (30 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/heptane 0:1 to 3:7) to give 3′,6′-dihydro-2′H-[2,4]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester (1.13 g, 78%). 1H-NMR (400 MHz, d6-DMSO): δ=1.31-1.38 (t, 3H), 1.47 (s, 9H), 2.55-2.59 (m, 2H), 3.51-3.59 (m, 2H), 4.08-4.12 (m, 2H), 4.31-4.37 (q, 2H), 6.74 (m, 1H), 7.75-7.79 (d, 1H), 7.88-7.91 (m, 1H), 7.92-7.99 (t, 1H). MS: m/z=333 (M+1).
    • b) Preparation of 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester
  • A solution of 3′,6′-dihydro-2′H-[2,4]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester (1.12 g, 3.37 mmol) in ethanol (67 mL) was pumped through Pd/C cartridge using H-Cube apparatus (20° C., 10 bar, 2 mL/min.). The solvent was then evaporated under reduce pressure to give 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester (1.001 g, 89%), which can be used in the next step without further purification. 1H-NMR (400 MHz, d6-DMSO): δ=1.31-1.38 (t, 3H), 1.47 (s, 9H), 1.55-1.65 (m, 2H), 1.79-1.88 (m, 2H), 2.91-2.99 (m, 2H), 3.42-3.48 (m, 1H), 4.05-4.12 (m, 2H), 4.31-4.37 (q, 2H), 7.55 (d, 1H), 7.84-7.92 (m, 2H). MS: m/z=333 (M+1. MS: m/z=335 (M+1).
    • c) Preparation of 3′,4′,5′,6′-tetrahydro-2′H-[2,4]bipyridinyl-6,1-dicarboxylic acid 1′-tert-butyl ester
  • To a solution of 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester 6-ethyl ester (100 mg, 0.3 mmol) in methanol (5 mL) was added aq. solution of sodium hydroxide (2 M, 0.23 mL, 0.5 mmol) at RT. After stirring for 4 h at RT, the solvent was removed, and the residue was dissolved in THF (5 mL), and aq. solution of lithium hydroxide (7 mg in 1 mL of water) was added at RT. After stirring overnight at RT, the solvent was removed and the residue was dissolved in ethylacetate (10 mL) and the reaction mixture was acidified with 2M aq. solution of HCl until pH 2-3. After separation of phases, the aq. layer was re-extracted with ethylacetate (10 mL), and the combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure to give 3′,4′,5′,6′-tetrahydro-2′H-[2,4]bipyridinyl-6,1-dicarboxylic acid 1′-tert-butyl ester (45 mg, 49%), which can be used in the next step without further purification. 1H-NMR (400 MHz, d6-DMSO): δ=1.43 (s, 9H), 1.58-1.68 (m, 2H), 1.81-1.84 (m, 2H), 2.84-2.96 (m, 2H), 3.27-3.39 (m, 1H), 4.07-4.10 (m, 2H), 7.52-7.54 (d, 1H), 7.86-7.92 (m, 2H). MS: m/z=329 (M+23).
    • d) Preparation of 6-[methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-carbamoyl]-3′,4′,5′,6′-tetrahydro-2′H-[2,4]bipyridinyl-1′-carboxylic acid tert-butyl ester
  • To a solution of 3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-6,1′-dicarboxylic acid 1′-tert-butyl ester (150 mg, 0.49 mmol), methyl-(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-amine (0.079 g, 0.49 mmol), and diisopropylethylamine (0.50 mL, 0.49 mmol) in DMF (10 mL) was added dropwise BOP (238 mg, 0.49 mmol) at RT. After stirring overnight at RT, the reaction mixture was poured on water (10 mL) and extracted with ethylacetate (20 mL). The aqueous phase was re-extracted with ethylacetate (20 mL). The combined organic layers were washed with aq. sat. sodium bicarbonate solution (30 mL), 1M HCl solution (30 mL) and brine (30 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/hexane 4:1) to give 6-[methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-carbamoyl]-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1-carboxylic acid tert-butyl ester (215 mg, 97%). 1H-NMR (400 MHz, CDCl3): δ=1.47 (s, 9H), 1.64-2.05 (m, 8H), 2.18-2.22 (m, 1H), 2.72-2.81 (m, 4H), 2.82 (s, 3H), 4.15-4.25 (m, 2H), 5.15-5.20 (m, 1H), 7.18-7.25 (m, 5H), 7.53-7.71 (m, 1H), 7.73-7.74 (m, 1H).
    • e) Preparation of 1,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide hydrochloride salt
  • To a solution of 6-[methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-carbamoyl]-3′,4′,5′,6′-tetrahydro-2′H-[2,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester (202 mg, 0.45 mmol) was added a solution of 4M HCl in dioxane (1.13 mL, 4.5 mmol)) at RT. After stirring overnight at RT, the solvent was evaporated under reduce pressure to give 1′,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide hydrochloride salt (162 mg, 93%). 1H-NMR (400 MHz, d6-DMSO): δ=1.83-2.02 (m, 6H), 2.51 (s, 3H), 2.52-2.59 (m, 2H), 2.71-3.03 (m, 2H), 3.29-3.38 (m, 2H), 3.97-4.05 (m, 2H), 4.78-4.83 (m, 1H), 7.08-7.23 (m, 4H), 7.36-7.41 (m, 1H), 7.52-7.55 (m, 1H), 7.90-7.95 (m, 1H), 8.81 (br, 1H), 9.04 (br, 1H).
    • f) Preparation of 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4′]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (Compound No. I.q.005)
  • To a solution of (5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid (81 mg, 0.39 mmol), 1,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide hydrochloride salt (150 mg, 0.39 mmol), and diisopropylethylamine (0.41 mL, 0.39 mmol) in DMF (10 mL) was added dropwise BOP (191 mg, 0.39 mmol) at RT. After stirring overnight at RT, the reaction mixture was poured on water (10 mL) and extracted with ethylacetate (20 mL). The aqueous phase was re-extracted with ethylacetate (20 mL). The combined organic layers were washed with aq. sat. sodium bicarbonate solution (30 mL), 1M HCl solution (30 mL) and brine (30 mL), dried over sodium sulfate, filtered, and evaporated under reduce pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate) to give 1′-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1′,2′,3′,4′,5′,6′-hexahydro-[2,4]bipyridinyl-6-carboxylic acid methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amide (150 mg, 71%). M.p 62-65° C. 1H-NMR (400 MHz, CDCl3): δ=1.67-2.02 (m, 6H), 2.18-2.22 (m, 1H), 2.30 (s, 3H), 2.71 (s, 3H), 2.72-2.75 (m, 2H), 3.17-3.27 (m, 2H), 3.97-4.05 (m, 2H), 4.58-4.78 (m, 2H), 4.96 (s, 2H), 5.05-5.15 (m, 1H), 6.33 (s, 1H), 7.10-7.24 (m, 4H), 7.28-7.32 (m, 1H), 7.57-7.58 (m, 1H), 7.76-7.78 (m, 1H).
  • Table 1 below illustrates examples of individual compounds of formula I according to the invention.
  • TABLE 1
    individual compounds of formula I according to the invention
    Compound
    No. R1 A Q R9
    001
    Figure US20130144064A1-20130606-C00045
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00046
    002
    Figure US20130144064A1-20130606-C00047
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00048
    003
    Figure US20130144064A1-20130606-C00049
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00050
    004
    Figure US20130144064A1-20130606-C00051
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00052
    005
    Figure US20130144064A1-20130606-C00053
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00054
    006
    Figure US20130144064A1-20130606-C00055
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00056
    007
    Figure US20130144064A1-20130606-C00057
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00058
    008
    Figure US20130144064A1-20130606-C00059
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00060
    009
    Figure US20130144064A1-20130606-C00061
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00062
    010
    Figure US20130144064A1-20130606-C00063
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00064
    011
    Figure US20130144064A1-20130606-C00065
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00066
    012
    Figure US20130144064A1-20130606-C00067
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00068
    013
    Figure US20130144064A1-20130606-C00069
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00070
    014
    Figure US20130144064A1-20130606-C00071
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00072
    015
    Figure US20130144064A1-20130606-C00073
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00074
    016
    Figure US20130144064A1-20130606-C00075
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00076
    017
    Figure US20130144064A1-20130606-C00077
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00078
    018
    Figure US20130144064A1-20130606-C00079
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00080
    019
    Figure US20130144064A1-20130606-C00081
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00082
    020
    Figure US20130144064A1-20130606-C00083
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00084
    021
    Figure US20130144064A1-20130606-C00085
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00086
    022
    Figure US20130144064A1-20130606-C00087
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00088
    023
    Figure US20130144064A1-20130606-C00089
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00090
    024
    Figure US20130144064A1-20130606-C00091
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00092
    025
    Figure US20130144064A1-20130606-C00093
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00094
    026
    Figure US20130144064A1-20130606-C00095
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00096
    027
    Figure US20130144064A1-20130606-C00097
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00098
    028
    Figure US20130144064A1-20130606-C00099
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00100
    029
    Figure US20130144064A1-20130606-C00101
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00102
    030
    Figure US20130144064A1-20130606-C00103
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00104
    031
    Figure US20130144064A1-20130606-C00105
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00106
    032
    Figure US20130144064A1-20130606-C00107
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00108
    033
    Figure US20130144064A1-20130606-C00109
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00110
    034
    Figure US20130144064A1-20130606-C00111
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00112
    035
    Figure US20130144064A1-20130606-C00113
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00114
    036
    Figure US20130144064A1-20130606-C00115
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00116
    037
    Figure US20130144064A1-20130606-C00117
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00118
    038
    Figure US20130144064A1-20130606-C00119
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00120
    039
    Figure US20130144064A1-20130606-C00121
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00122
    040
    Figure US20130144064A1-20130606-C00123
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00124
    041
    Figure US20130144064A1-20130606-C00125
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00126
    042
    Figure US20130144064A1-20130606-C00127
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00128
    043
    Figure US20130144064A1-20130606-C00129
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00130
    044
    Figure US20130144064A1-20130606-C00131
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00132
    045
    Figure US20130144064A1-20130606-C00133
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00134
    046
    Figure US20130144064A1-20130606-C00135
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00136
    047
    Figure US20130144064A1-20130606-C00137
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00138
    048
    Figure US20130144064A1-20130606-C00139
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00140
    049
    Figure US20130144064A1-20130606-C00141
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00142
    050
    Figure US20130144064A1-20130606-C00143
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00144
    051
    Figure US20130144064A1-20130606-C00145
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00146
    052
    Figure US20130144064A1-20130606-C00147
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00148
    053
    Figure US20130144064A1-20130606-C00149
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00150
    054
    Figure US20130144064A1-20130606-C00151
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00152
    055
    Figure US20130144064A1-20130606-C00153
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00154
    056
    Figure US20130144064A1-20130606-C00155
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00156
    057
    Figure US20130144064A1-20130606-C00157
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00158
    058
    Figure US20130144064A1-20130606-C00159
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00160
    059
    Figure US20130144064A1-20130606-C00161
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00162
    060
    Figure US20130144064A1-20130606-C00163
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00164
    061
    Figure US20130144064A1-20130606-C00165
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00166
    062
    Figure US20130144064A1-20130606-C00167
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00168
    063
    Figure US20130144064A1-20130606-C00169
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00170
    064
    Figure US20130144064A1-20130606-C00171
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00172
    065
    Figure US20130144064A1-20130606-C00173
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00174
    066
    Figure US20130144064A1-20130606-C00175
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00176
    067
    Figure US20130144064A1-20130606-C00177
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00178
    068
    Figure US20130144064A1-20130606-C00179
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00180
    069
    Figure US20130144064A1-20130606-C00181
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00182
    070
    Figure US20130144064A1-20130606-C00183
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00184
    071
    Figure US20130144064A1-20130606-C00185
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00186
    072
    Figure US20130144064A1-20130606-C00187
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00188
    073
    Figure US20130144064A1-20130606-C00189
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00190
    074
    Figure US20130144064A1-20130606-C00191
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00192
    075
    Figure US20130144064A1-20130606-C00193
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00194
    076
    Figure US20130144064A1-20130606-C00195
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00196
    077
    Figure US20130144064A1-20130606-C00197
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00198
    078
    Figure US20130144064A1-20130606-C00199
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00200
    079
    Figure US20130144064A1-20130606-C00201
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00202
    080
    Figure US20130144064A1-20130606-C00203
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00204
    081
    Figure US20130144064A1-20130606-C00205
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00206
    082
    Figure US20130144064A1-20130606-C00207
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00208
    083
    Figure US20130144064A1-20130606-C00209
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00210
    084
    Figure US20130144064A1-20130606-C00211
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00212
    085
    Figure US20130144064A1-20130606-C00213
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00214
    086
    Figure US20130144064A1-20130606-C00215
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00216
    087
    Figure US20130144064A1-20130606-C00217
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00218
    088
    Figure US20130144064A1-20130606-C00219
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00220
    089
    Figure US20130144064A1-20130606-C00221
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00222
    090
    Figure US20130144064A1-20130606-C00223
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00224
    091
    Figure US20130144064A1-20130606-C00225
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00226
    092
    Figure US20130144064A1-20130606-C00227
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00228
    093
    Figure US20130144064A1-20130606-C00229
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00230
    094
    Figure US20130144064A1-20130606-C00231
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00232
    095
    Figure US20130144064A1-20130606-C00233
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00234
    096
    Figure US20130144064A1-20130606-C00235
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00236
    097
    Figure US20130144064A1-20130606-C00237
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00238
    098
    Figure US20130144064A1-20130606-C00239
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00240
    099
    Figure US20130144064A1-20130606-C00241
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00242
    100
    Figure US20130144064A1-20130606-C00243
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00244
    101
    Figure US20130144064A1-20130606-C00245
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00246
    102
    Figure US20130144064A1-20130606-C00247
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00248
    103
    Figure US20130144064A1-20130606-C00249
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00250
    104
    Figure US20130144064A1-20130606-C00251
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00252
    105
    Figure US20130144064A1-20130606-C00253
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00254
    106
    Figure US20130144064A1-20130606-C00255
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00256
    107
    Figure US20130144064A1-20130606-C00257
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00258
    108
    Figure US20130144064A1-20130606-C00259
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00260
    109
    Figure US20130144064A1-20130606-C00261
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00262
    110
    Figure US20130144064A1-20130606-C00263
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00264
    111
    Figure US20130144064A1-20130606-C00265
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00266
    112
    Figure US20130144064A1-20130606-C00267
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00268
    113
    Figure US20130144064A1-20130606-C00269
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00270
    114
    Figure US20130144064A1-20130606-C00271
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00272
    115
    Figure US20130144064A1-20130606-C00273
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00274
    116
    Figure US20130144064A1-20130606-C00275
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00276
    117
    Figure US20130144064A1-20130606-C00277
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00278
    118
    Figure US20130144064A1-20130606-C00279
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00280
    119
    Figure US20130144064A1-20130606-C00281
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00282
    120
    Figure US20130144064A1-20130606-C00283
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00284
    121
    Figure US20130144064A1-20130606-C00285
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00286
    122
    Figure US20130144064A1-20130606-C00287
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00288
    123
    Figure US20130144064A1-20130606-C00289
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00290
    124
    Figure US20130144064A1-20130606-C00291
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00292
    125
    Figure US20130144064A1-20130606-C00293
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00294
    126
    Figure US20130144064A1-20130606-C00295
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00296
    127
    Figure US20130144064A1-20130606-C00297
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00298
    128
    Figure US20130144064A1-20130606-C00299
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00300
    129
    Figure US20130144064A1-20130606-C00301
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00302
    130
    Figure US20130144064A1-20130606-C00303
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00304
    131
    Figure US20130144064A1-20130606-C00305
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00306
    132
    Figure US20130144064A1-20130606-C00307
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00308
    133
    Figure US20130144064A1-20130606-C00309
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00310
    134
    Figure US20130144064A1-20130606-C00311
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00312
    135
    Figure US20130144064A1-20130606-C00313
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00314
    136
    Figure US20130144064A1-20130606-C00315
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00316
    137
    Figure US20130144064A1-20130606-C00317
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00318
    138
    Figure US20130144064A1-20130606-C00319
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00320
    139
    Figure US20130144064A1-20130606-C00321
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00322
    140
    Figure US20130144064A1-20130606-C00323
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00324
    141
    Figure US20130144064A1-20130606-C00325
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00326
    142
    Figure US20130144064A1-20130606-C00327
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00328
    143
    Figure US20130144064A1-20130606-C00329
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00330
    144
    Figure US20130144064A1-20130606-C00331
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00332
    145
    Figure US20130144064A1-20130606-C00333
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00334
    146
    Figure US20130144064A1-20130606-C00335
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00336
    147
    Figure US20130144064A1-20130606-C00337
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00338
    148
    Figure US20130144064A1-20130606-C00339
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00340
    149
    Figure US20130144064A1-20130606-C00341
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00342
    150
    Figure US20130144064A1-20130606-C00343
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00344
    151
    Figure US20130144064A1-20130606-C00345
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00346
    152
    Figure US20130144064A1-20130606-C00347
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00348
    153
    Figure US20130144064A1-20130606-C00349
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00350
    154
    Figure US20130144064A1-20130606-C00351
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00352
    155
    Figure US20130144064A1-20130606-C00353
         		—CH2C(═O)— O
    Figure US20130144064A1-20130606-C00354
    156
    Figure US20130144064A1-20130606-C00355
         		—CH2C(═O)— S
    Figure US20130144064A1-20130606-C00356
    157
    Figure US20130144064A1-20130606-C00357
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00358
    158
    Figure US20130144064A1-20130606-C00359
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00360
    159
    Figure US20130144064A1-20130606-C00361
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00362
    160
    Figure US20130144064A1-20130606-C00363
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00364
    161
    Figure US20130144064A1-20130606-C00365
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00366
    162
    Figure US20130144064A1-20130606-C00367
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00368
    163
    Figure US20130144064A1-20130606-C00369
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00370
    164
    Figure US20130144064A1-20130606-C00371
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00372
    165
    Figure US20130144064A1-20130606-C00373
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00374
    166
    Figure US20130144064A1-20130606-C00375
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00376
    167
    Figure US20130144064A1-20130606-C00377
         		—CH2C(═S)— O
    Figure US20130144064A1-20130606-C00378
    168
    Figure US20130144064A1-20130606-C00379
         		—CH2C(═S)— S
    Figure US20130144064A1-20130606-C00380
    169
    Figure US20130144064A1-20130606-C00381
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00382
    170
    Figure US20130144064A1-20130606-C00383
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00384
    171
    Figure US20130144064A1-20130606-C00385
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00386
    172
    Figure US20130144064A1-20130606-C00387
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00388
    173
    Figure US20130144064A1-20130606-C00389
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00390
    174
    Figure US20130144064A1-20130606-C00391
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00392
    175
    Figure US20130144064A1-20130606-C00393
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00394
    176
    Figure US20130144064A1-20130606-C00395
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00396
    177
    Figure US20130144064A1-20130606-C00397
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00398
    178
    Figure US20130144064A1-20130606-C00399
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00400
    179
    Figure US20130144064A1-20130606-C00401
         		—OC(═O)— O
    Figure US20130144064A1-20130606-C00402
    180
    Figure US20130144064A1-20130606-C00403
         		—OC(═O)— S
    Figure US20130144064A1-20130606-C00404
    181
    Figure US20130144064A1-20130606-C00405
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00406
    182
    Figure US20130144064A1-20130606-C00407
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00408
    183
    Figure US20130144064A1-20130606-C00409
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00410
    184
    Figure US20130144064A1-20130606-C00411
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00412
    185
    Figure US20130144064A1-20130606-C00413
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00414
    186
    Figure US20130144064A1-20130606-C00415
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00416
    187
    Figure US20130144064A1-20130606-C00417
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00418
    188
    Figure US20130144064A1-20130606-C00419
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00420
    189
    Figure US20130144064A1-20130606-C00421
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00422
    190
    Figure US20130144064A1-20130606-C00423
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00424
    191
    Figure US20130144064A1-20130606-C00425
         		—CH2SO2— O
    Figure US20130144064A1-20130606-C00426
    192
    Figure US20130144064A1-20130606-C00427
         		—CH2SO2— S
    Figure US20130144064A1-20130606-C00428

    where
    a) 192 compounds of formula (I.a):
  • Figure US20130144064A1-20130606-C00429
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    b) 192 compounds of formula (I.b):
  • Figure US20130144064A1-20130606-C00430
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    c) 192 compounds of formula (I.c):
  • Figure US20130144064A1-20130606-C00431
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    d) 192 compounds of formula (I.d):
  • Figure US20130144064A1-20130606-C00432
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    e) 192 compounds of formula (I.e):
  • Figure US20130144064A1-20130606-C00433
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    f) 192 compounds of formula (I.f):
  • Figure US20130144064A1-20130606-C00434
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    g) 192 compounds of formula (I.g):
  • Figure US20130144064A1-20130606-C00435
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    h) 192 compounds of formula (I.h):
  • Figure US20130144064A1-20130606-C00436
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    i) 192 compounds of formula (I.i):
  • Figure US20130144064A1-20130606-C00437
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    j) 192 compounds of formula (I.j):
  • Figure US20130144064A1-20130606-C00438
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    k) 192 compounds of formula (I.k):
  • Figure US20130144064A1-20130606-C00439
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    m) 192 compounds of formula (I.m):
  • Figure US20130144064A1-20130606-C00440
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    n) 192 compounds of formula (I.n):
  • Figure US20130144064A1-20130606-C00441
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    o) 192 compounds of formula (I.o):
  • Figure US20130144064A1-20130606-C00442
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    p) 192 compounds of formula (I.p):
  • Figure US20130144064A1-20130606-C00443
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    q) 192 compounds of formula (I.q):
  • Figure US20130144064A1-20130606-C00444
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    r) 192 compounds of formula (I.r):
  • Figure US20130144064A1-20130606-C00445
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    s) 192 compounds of formula (I.s):
  • Figure US20130144064A1-20130606-C00446
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    t) 192 compounds of formula (I.t):
  • Figure US20130144064A1-20130606-C00447
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    u) 192 compounds of formula (I.u):
  • Figure US20130144064A1-20130606-C00448
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    v) 192 compounds of formula (I.v):
  • Figure US20130144064A1-20130606-C00449
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    w) 192 compounds of formula (I.w):
  • Figure US20130144064A1-20130606-C00450
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    x) 192 compounds of formula (I.x):
  • Figure US20130144064A1-20130606-C00451
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    y) 192 compounds of formula (I.y):
  • Figure US20130144064A1-20130606-C00452
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    z) 192 compounds of formula (I.z):
  • Figure US20130144064A1-20130606-C00453
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    aa) 192 compounds of formula (Iaa):
  • Figure US20130144064A1-20130606-C00454
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ab) 192 compounds of formula (I.ab):
  • Figure US20130144064A1-20130606-C00455
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ac) 192 compounds of formula (I.ac):
  • Figure US20130144064A1-20130606-C00456
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ad) 192 compounds of formula (I.ad):
  • Figure US20130144064A1-20130606-C00457
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ae) 192 compounds of formula (I.ae):
  • Figure US20130144064A1-20130606-C00458
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    af) 192 compounds of formula (I.af):
  • Figure US20130144064A1-20130606-C00459
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ag) 192 compounds of formula (I.ag):
  • Figure US20130144064A1-20130606-C00460
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ah) 192 compounds of formula (I.ah):
  • Figure US20130144064A1-20130606-C00461
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ai) 192 compounds of formula (I.ai):
  • Figure US20130144064A1-20130606-C00462
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    aj) 192 compounds of formula (I.aj):
  • Figure US20130144064A1-20130606-C00463
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ak) 192 compounds of formula (Iak):
  • Figure US20130144064A1-20130606-C00464
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    am) 192 compounds of formula (I.am):
  • Figure US20130144064A1-20130606-C00465
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    an) 192 compounds of formula (I.an):
  • Figure US20130144064A1-20130606-C00466
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ao) 192 compounds of formula (I.ao):
  • Figure US20130144064A1-20130606-C00467
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ap) 192 compounds of formula (I.ap):
  • Figure US20130144064A1-20130606-C00468
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    aq) 192 compounds of formula (I.aq):
  • Figure US20130144064A1-20130606-C00469
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ar) 192 compounds of formula (I.ar):
  • Figure US20130144064A1-20130606-C00470
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    as) 192 compounds of formula (I.as):
  • Figure US20130144064A1-20130606-C00471
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    at) 192 compounds of formula (I.at):
  • Figure US20130144064A1-20130606-C00472
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    au) 192 compounds of formula (I.au):
  • Figure US20130144064A1-20130606-C00473
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    av) 192 compounds of formula (I.av):
  • Figure US20130144064A1-20130606-C00474
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    aw) 192 compounds of formula (I.aw):
  • Figure US20130144064A1-20130606-C00475
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ax) 192 compounds of formula (I.ax):
  • Figure US20130144064A1-20130606-C00476
  • wherein A, Q, R1 and R9 are as defined in Table 1.
    ay) 192 compounds of formula (I.ay):
  • Figure US20130144064A1-20130606-C00477
  • wherein A, Q, R1 and R9 are as defined in Table 1.
  • Throughout this description, temperatures are given in degrees Celsius and “m.p.” means melting point. LC/MS means Liquid Chromatography Mass Spectroscopy and the description of the apparatus and the method is: (HP 1100 HPLC from Agilent, Phenomenex Gemini C18, 3 μm particle size, 110 Angström, 30×3 mm column, 1.7 mL/min., 60° C., H2O+0.05% HCOOH (95%)/CH3CN/MeOH 4:1+0.04% HCOOH (5%)−2 min.−CH3CN/MeOH 4:1+0.04% HCOOH (5%)−0.8 min., ZQ Mass Spectrometer from Waters, ionization method: electrospray (ESI), Polarity: positive ions, Capillary (kV) 3.00, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (° C.) 100, Desolvation Temperature (° C.) 250, Cone Gas Flow (L/Hr) 50, Desolvation Gas Flow (L/Hr) 400)).
  • TABLE 2
    Melting point and LC/MS data for compounds of Table 1
    Compound Melting point
    No. (° C.) LC/MS
    l.n.001 Rt = 1.97 min.; MS: m/z = 525 (M + 1)
    l.n.003 215-217
    l.n.005 Rt = 1.96 min.; MS: m/z = 525 (M + 1)
    l.n.009 Rt = 3.46 min.; MS: m/z = 485 (M + 1)
    l.n.011 Rt = 1.85 min.; MS: m/z = 471 (M + 1)
    l.n.049 Rt = 2.08 min.; MS: m/z = 481 (M + 1)
    l.n.073 Rt = 2.17 min.; MS: m/z = 483 (M + 1)
    l.n.085 Rt = 2.12 min.; MS: m/z = 517 (M + 1)
    l.n.097 Rt = 1.80 min.; MS: m/z = 471 (M + 1)
    l.n.169 Rt = 2.11 min.; MS: m/z = 469 (M + 1)
    l.o.001 Rt = 2.03 min.; MS: m/z = 539 (M + 1)
    l.o.003 Rt = 1.95 min.; MS: m/z = 513 (M + 1)
    l.o.009 Rt = 1.88 min.; MS: m/z = 499 (M + 1)
    l.p.001 Rt = 1.97 min.; MS: m/z = 526 (M + 1)
    l.p003 Rt = 1.92 min.; MS: m/z = 500 (M + 1)
    l.p.005 Rt = 2.01 min.; MS: m/z = 526 (M + 1)
    l.p.009 Rt = 1.87 min.; MS: m/z = 486 (M + 1)
    l.p.011 Rt = 1.92 min.; MS: m/z = 472 (M + 1)
    l.p.049 Rt = 2.09 min.; MS: m/z = 482 (M + 1)
    l.p.073 Rt = 2.18 min.; MS: m/z = 484 (M + 1)
    l.p.085 Rt = 2.14 min.; MS: m/z = 518 (M + 1)
    l.p.097 Rt = 1.82 min.; MS: m/z = 472 (M + 1)
    l.q.001 Rt = 1.94 min.; MS: m/z = 540 (M + 1)
    l.q.005 62-65
    l.z.001 210
    l.z.005 Rt = 1.91 min.; MS: m/z = 526 (M + 1)
    l.z.011 Rt = 1.78 min.; MS: m/z = 472 (M + 1)
    l.z.073 183-185
    l.z.085 186-189
    l.aa.001 Rt = 1.98 min.; MS: m/z = 540 (M + 1)
    l.aa.011 Rt = 1.79 min.; MS: m/z = 486 (M + 1)
    l.v.001 Rt = 2.02 min.; MS: m/z = 526 (M + 1)
    l.w.001 Rt = 1.88 min.; MS: m/z = 540 (M + 1)
    l.r.001 Rt = 1.84 min.; MS: m/z = 526 (M + 1)
    l.ay.001 Rt = 1.99 min.; MS: m/z = 527 (M + 1)
    l.aw.001 Rt = 1.94 min.; MS: m/z = 527 (M + 1)
    l.t.001 140
    l.u.001 Rt = 1.85 min.; MS: m/z = 540 (M + 1)
  • The compounds according to the present invention can be prepared according to the above-mentioned reaction schemes, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I).
    • Biological Examples
  • Phytophthora infestans/Tomato/Leaf Disc Preventative (Tomato Late Blight)
  • Tomato leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 16° C. and 75% rh under a light regime of 24 h darkness followed by 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5-7 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.011, I.n.049, I.n.097, I.t.001, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Phytophthora infestans/Potato/Preventative (Potato Late Blight)
  • 2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying them with a sporangia suspension 2 days after application. The inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (5-7 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.049, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Phytophthora infestans/Potato/Long Lasting (Potato Late Blight)
  • 2-week old potato plants cv. Bintje are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying them with a sporangia suspension 6 days after application. The inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (9-11 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.097, I.t.001, I.v.001, I.z.001 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Phytophthora infestans/Potato/Curative (Potato Late Blight)
  • 2-week old potato plants cv. Bintje are inoculated by spraying them with a sporangia suspension one day before application. The inoculated plants are sprayed in a spray chamber with the formulated test compound diluted in water. The inoculated test plants are incubated at 18° C. with 14 h light/day and 100% rh in a growth chamber and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (3-4 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.009, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Plasmopara viticola/Grape/Leaf Disc Preventative (Grape Downy Mildew)
  • Grape vine leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 19° C. and 80% rh under a light regime of 12 h light/12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6-8 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.009, I.n.011, I.n.049, I.n.097, I.t.001, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Plasmopara viticola/Grape/Preventative (Grape Downy Mildew)
  • 5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants plants are inoculated by spraying a sporangia suspension on their lower leaf surface one day after application. The inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (6-8 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.009, I.n.011, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Plasmopara viticola/Grape/Long Lasting (Grape Downy Mildew)
  • 5-week old grape seedlings cv. Gutedel are sprayed in a spray chamber with the formulated test compound diluted in water. The test plants are inoculated by spraying a sporangia suspension on their lower leaf surface 6 days after application. The inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (11-13 days after application).
  • Compounds I.n.001, I.n.003, I.n.005, I.n.009, I.t.001, I.v.001, I.z.001 and I.z.005 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.
  • Plasmopara viticola/Grape/Curative (Grape Downy Mildew)
  • 5-week-old grape seedlings cv. Gutedel are inoculated by spraying a sporangia suspension on their lower leaf surface one day before application. The inoculated grape plants are sprayed in a spray chamber with the formulated test compound diluted in water. The inoculated test plants are incubated at 22° C. and 100% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (4-6 days after application).
  • Compound I.n.001, I.n.003, I.n.005, I.n.009, I.n.049, I.v.001 and I.z.001 at 200 ppm give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Claims (2)

What is claimed is:
1. A compound of formula I.a:
Figure US20130144064A1-20130606-C00478
wherein R1′ is C1-C8 alkyl and Y1, Y2, Y3, Y4, A, Q, T, n, p, R2, R3, R4, R5, R6, R7, R8, and R9 have the definitions as described for formula I as defined in any one of claims 1 to 10;
or a compound of formula II:
Figure US20130144064A1-20130606-C00479
wherein Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7 have the definitions as described for formula I as defined in any one of claims 1 to 10;
or a compound of formula IV:
Figure US20130144064A1-20130606-C00480
wherein Y1, Y2, Y3, Y4, A, Q, T, n, p, R1, R2, R3, R4, R5, R6 and R7 have the definitions as described for formula I as defined in any one of claims 1 to 10; and
R26 is C1-C6 alkyl or optionally substituted aryl;
or a compound of formula V:
Figure US20130144064A1-20130606-C00481
wherein Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R6 and R7, have the definitions as described for formula I as defined in any one of claims 1 to 10; and
R26 is C1-C6 alkyl or optionally substituted aryl;
or a compound of formula X:
Figure US20130144064A1-20130606-C00482
wherein Y1, Y2, Y3, Y4, Q, n, p, R2, R3, R4, R6 and R7 have the definitions as described for formula I as defined in any one of claims 1 to 10; and R26 is C1-C6 alkyl or optionally substituted aryl;
or a compound of formula XI:
Figure US20130144064A1-20130606-C00483
wherein Y1, Y2, Y3, Y4, A, Q, n, p, R1, R2, R3, R4, R5, R6 and R7, have the definitions as described for formula I as defined in any one of claims 1 to 10; and Hal stands for halogen.
2. A compound according to claim 1, wherein R26 is C1-C6 alkyl or phenyl optionally substituted with 1 to 3 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, hydroxyl, amino, cyano and halogen.
US13/759,761 2009-08-12 2013-02-05 Microbiocidal heterocycles Abandoned US20130144064A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/759,761 US20130144064A1 (en) 2009-08-12 2013-02-05 Microbiocidal heterocycles

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09167741 2009-08-12
EP09167741.9 2009-08-12
PCT/EP2010/061464 WO2011018415A2 (en) 2009-08-12 2010-08-06 Microbiocidal heterocycles
US201213390023A 2012-02-10 2012-02-10
US13/759,761 US20130144064A1 (en) 2009-08-12 2013-02-05 Microbiocidal heterocycles

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2010/061464 Continuation WO2011018415A2 (en) 2009-08-12 2010-08-06 Microbiocidal heterocycles
US201213390023A Continuation 2009-08-12 2012-02-10

Publications (1)

Publication Number Publication Date
US20130144064A1 true US20130144064A1 (en) 2013-06-06

Family

ID=42683487

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/390,023 Expired - Fee Related US8367844B2 (en) 2009-08-12 2010-08-06 Microbiocidal heterocycles
US13/759,761 Abandoned US20130144064A1 (en) 2009-08-12 2013-02-05 Microbiocidal heterocycles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/390,023 Expired - Fee Related US8367844B2 (en) 2009-08-12 2010-08-06 Microbiocidal heterocycles

Country Status (33)

Country Link
US (2) US8367844B2 (en)
EP (1) EP2464630B1 (en)
JP (1) JP5778674B2 (en)
KR (1) KR101750027B1 (en)
CN (1) CN102471277B (en)
AP (1) AP3383A (en)
AR (1) AR077835A1 (en)
AU (1) AU2010283767B2 (en)
BR (1) BR112012003124A2 (en)
CA (1) CA2768636C (en)
CL (1) CL2012000339A1 (en)
CO (1) CO6612179A2 (en)
CR (1) CR20120064A (en)
EA (1) EA021137B1 (en)
ES (1) ES2588330T3 (en)
GE (1) GEP20146113B (en)
HN (1) HN2012000308A (en)
HR (1) HRP20160951T1 (en)
HU (1) HUE029097T2 (en)
IL (1) IL217645A (en)
JO (1) JO3140B1 (en)
MX (1) MX2012001689A (en)
MY (1) MY157410A (en)
NI (1) NI201200025A (en)
NZ (1) NZ597503A (en)
PL (1) PL2464630T3 (en)
PT (1) PT2464630T (en)
SA (1) SA110310646B1 (en)
TW (1) TWI488849B (en)
UA (1) UA107938C2 (en)
UY (1) UY32840A (en)
WO (1) WO2011018415A2 (en)
ZA (1) ZA201200368B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5960683B2 (en) 2010-04-28 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ketoheteroarylpiperidine and -piperazine derivatives as fungicides
CN103025723A (en) * 2010-05-27 2013-04-03 拜尔农作物科学股份公司 Pyridinylcarboxylic acid derivatives as fungicides
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
CN107033139B (en) 2010-10-27 2019-11-19 拜耳知识产权有限责任公司 Heteroaryl piperidine and heteroaryl based piperazine derivative as fungicide
MX359992B (en) * 2011-06-30 2018-10-18 Syngenta Participations Ag Microbiocidal heterocycles.
ES2654573T3 (en) * 2011-12-27 2018-02-14 Bayer Intellectual Property Gmbh Heteroarylpiperidine and heteroarylpiperazine derivatives
SG11201404144PA (en) 2012-02-02 2014-10-30 Actelion Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
US10035790B2 (en) * 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
TWI632142B (en) 2013-06-24 2018-08-11 德商拜耳作物科學股份有限公司 Piperidinecarboxylic acid derivatives as fungicides
CN105658649B (en) 2013-07-22 2019-03-22 爱杜西亚药品有限公司 1- (piperazine -1- base) -2- ([1,2,4] triazol-1-yl)-ethanone derivatives
WO2015028457A1 (en) 2013-08-28 2015-03-05 Bayer Cropscience Ag Malonic ester derivatives of heteroarylpiperidines and -piperazines as fungicides
JP2017512788A (en) 2014-03-24 2017-05-25 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Phenyl piperidine carboxamide derivatives as fungicides
AR099789A1 (en) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd DERIVATIVES OF 8- (PIPERAZIN-1-IL) -1,2,3,4-TETRAHYDRO-ISOQUINOLINE
CA2956405A1 (en) 2014-07-31 2016-02-04 Syngenta Participations Ag Fungicidal compositions
WO2016024350A1 (en) 2014-08-13 2016-02-18 株式会社エス・ディー・エス バイオテック Condensed 11-membered ring compounds and agricultural and horticultural fungicide containing same
AR103399A1 (en) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd DERIVATIVES OF (R) -2-METHYL-PIPERAZINE AS CXCR3 RECEIVER MODULATORS
ES2709985T3 (en) 2015-01-15 2019-04-22 Idorsia Pharmaceuticals Ltd Hydroxyalkyl piperazine derivatives as modulators of the CXCR3 receptor
EP3415008A4 (en) 2016-02-08 2019-09-11 SDS Biotech K. K. Germicidal composition
PT3415496T (en) 2016-02-08 2021-10-25 Gowan Crop Prot Limited Method for producing 1, 2-benzene dimethanol compound
CN109414596B (en) * 2016-05-12 2023-09-29 密歇根大学董事会 ASH1L inhibitors and methods of treatment therewith
WO2019040703A1 (en) 2017-08-23 2019-02-28 Magna Mirrors Of America, Inc. Interior rearview mirror assembly with full screen video display
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
CN114380802B (en) * 2022-01-07 2023-11-17 贵州大学 Carbazolyl-containing imidazole salt compound, and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340685C (en) 1988-07-29 1999-07-27 Frederick Meins Dna sequences encoding polypeptides having beta-1,3-glucanase activity
ATE241699T1 (en) 1989-03-24 2003-06-15 Syngenta Participations Ag DISEASE RESISTANT TRANSGENIC PLANT
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
JP2000506171A (en) 1996-03-11 2000-05-23 ノバルティス アクチェンゲゼルシャフト Pyrimidin-4-one derivatives as pesticides
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
GB0214406D0 (en) 2002-06-21 2002-07-31 Plant Bioscience Ltd Plant-derived transferase genes
DE60326752D1 (en) * 2002-11-26 2009-04-30 Pfizer Prod Inc PHENYL SUBTITUED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS
KR20060003353A (en) 2003-04-15 2006-01-10 머크 앤드 캄파니 인코포레이티드 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
JP4809228B2 (en) * 2003-09-24 2011-11-09 メチルジーン インコーポレイテッド Inhibitors of histone deacetylase
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
EP1765320A2 (en) * 2004-05-25 2007-03-28 Pfizer Products Incorporated Use of ppar agonists to treat ruminants
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
BRPI0806214A2 (en) 2007-01-25 2011-08-30 Du Pont compound, method for the control of plant diseases caused by oomycete fungal plant pathogens and fungicidal compositions
WO2009034390A1 (en) * 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
TWI428091B (en) 2007-10-23 2014-03-01 Du Pont Fungicidal mixtures
JP2011511056A (en) * 2008-02-05 2011-04-07 ファイザー・インク Pyridinylamide for the treatment of CNS and metabolic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists

Also Published As

Publication number Publication date
CA2768636C (en) 2017-06-13
NZ597503A (en) 2013-11-29
KR101750027B1 (en) 2017-06-22
IL217645A (en) 2015-03-31
PT2464630T (en) 2016-07-14
JP2013501745A (en) 2013-01-17
CN102471277A (en) 2012-05-23
CR20120064A (en) 2012-03-22
EA201200259A1 (en) 2012-09-28
WO2011018415A3 (en) 2011-08-18
ZA201200368B (en) 2012-09-26
AP3383A (en) 2015-07-31
JO3140B1 (en) 2017-09-20
SA110310646B1 (en) 2013-10-03
BR112012003124A2 (en) 2020-08-25
CL2012000339A1 (en) 2012-10-12
EA021137B1 (en) 2015-04-30
CO6612179A2 (en) 2013-02-01
AU2010283767B2 (en) 2015-04-09
EP2464630B1 (en) 2016-05-25
AP2012006152A0 (en) 2012-04-30
CN102471277B (en) 2015-05-06
ES2588330T3 (en) 2016-11-02
WO2011018415A2 (en) 2011-02-17
HUE029097T2 (en) 2017-02-28
PL2464630T3 (en) 2016-12-30
TWI488849B (en) 2015-06-21
KR20120048010A (en) 2012-05-14
MX2012001689A (en) 2012-02-22
MY157410A (en) 2016-06-15
NI201200025A (en) 2012-10-29
UA107938C2 (en) 2015-03-10
CA2768636A1 (en) 2011-02-17
US20120142698A1 (en) 2012-06-07
HRP20160951T1 (en) 2016-10-07
EP2464630A2 (en) 2012-06-20
AU2010283767A1 (en) 2012-02-23
AR077835A1 (en) 2011-09-28
GEP20146113B (en) 2014-06-25
TW201114755A (en) 2011-05-01
UY32840A (en) 2011-03-31
HN2012000308A (en) 2015-01-05
US8367844B2 (en) 2013-02-05
JP5778674B2 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
US8367844B2 (en) Microbiocidal heterocycles
US8748432B2 (en) Microbiocidal pyrazole derivatives
US8557821B2 (en) Microbiocidal heterocycles
US8629286B2 (en) Pyrazole derivatives
EP2643312B1 (en) Microbicidal heterocycles
US20150031541A1 (en) Microbiocidal pyrazole derivatives
US20140228372A1 (en) Microbiocidal pyrazole derivatives
US20160007606A1 (en) Microbiocidal pyrazole derivatives
US20130317064A1 (en) Microbiocidal pyrazole derivatives
US20140243371A1 (en) Microbiocidal pyrazole derivatives
WO2013000941A1 (en) Microbiocidal heterocycles
US9301530B2 (en) Microbiocidal heterocycles
US20150065481A1 (en) Microbiocidal pyrazole derivatives
OA16803A (en) Microbiocidal heterocycles.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION